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Abstract 
 
 
This thesis addresses the impact of quadriceps wasting and physical inactivity across 
disease severity (GOLD stages I-IV) in Chronic Obstructive Pulmonary Disease (COPD) and 
assesses the influence of angiotensin-converting enzyme (ACE)-inhibition on quadriceps 
dysfunction in these patients.  
 
In a cross-sectional study of 161 COPD patients, ultrasound measurement of rectus 
femoris cross-sectional area was reduced in mild as well as advanced disease when 
compared to controls. Daily physical activity, measured using an armband accelerometer, 
was reduced in COPD subjects across all GOLD stages compared to controls. Physical 
activity was independently associated with quadriceps wasting in GOLD stage I, but not 
stage II-IV disease where residual volume to total lung capacity ratio was the only 
independent predictor of activity level. This data suggests that quadriceps wasting is not 
an end-stage phenomenon in COPD and highlights the need for early identification of 
these patients to guide lifestyle and therapeutic interventions. 
 
The effect of the ACE-inhibitor, fosinopril on quadriceps dysfunction in COPD was then 
investigated in a double-blind randomised controlled trial of 80 COPD patients with 
quadriceps weakness. Despite a significant reduction in systolic blood pressure and serum 
ACE activity in the treatment group compared to placebo, no significant differences were 
observed at 3 months in the primary outcome of non-volitional quadriceps endurance. 
Quadriceps strength improved in both groups, but there was a greater increase in the 
placebo arm. No significant changes were observed in mid-thigh cross-sectional area or 
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incremental shuttle walk distance. The trial also assessed the effect of ACE-inhibition on 
vastus lateralis atrogene expression in COPD, with no significant differences observed 
between groups.  
 
In conclusion, although evidence from observational cohorts suggest a role for the renin-
angiotensin system in the control of muscle phenotype, data from this thesis found that 
ACE-inhibition did not improve quadriceps function in a COPD population with quadriceps 
weakness.  
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1.1 Definition of COPD 
 
 
The term ‘Chronic Obstructive Pulmonary Disease’ (COPD) was first introduced in the 
1960s describing patients with incompletely reversible airflow limitation due to the 
combined effects of airways disease, chronic bronchitis and emphysema (Briscoe 1965). It 
was the seminal work of a French clinician and pathologist, Laennec, who in 1821 originally 
described emphysema at dissection (Laennec 1821). On opening the chest, he noted: 
 
‘it is not unusual to find that the lungs do not collapse, but they fill up the cavity on each 
side of the heart. When experienced, this will appear full of air’  
 
Laennec went on to describe an accumulation of bronchial mucous in his dissection 
findings, so linking emphysema to the sputum production associated with chronic 
bronchitis (Petty 2006). Emphysema is now defined as abnormal, permanently enlarged 
airspaces distal to terminal bronchioles, with destruction of airspace walls.  Small airways 
disease (obstructive bronchiolitis) is caused by inflammation and squamous metaplasia in 
airways less than 2mm in diameter and can be among the first changes to appear from 
inhalation of noxious materials such as cigarette smoke (MacNee 2008). 
 
Today, the term COPD encompasses a range of pathologies including chronic bronchitis, 
obstructive bronchiolitis and emphysema and is characterised by airflow limitation 
associated with an abnormal inflammatory response in the lungs to inhalation of noxious 
substances, including tobacco smoke and, in the developing world, biomass smoke. The 
airflow obstruction is not fully reversible and is usually progressive causing breathlessness 
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and limitation of daily activities. It is estimated that currently over 210 million people 
worldwide suffer from COPD and World Health Organisation (WHO) projections suggest 
that COPD will be the 5th leading cause of disability (Murray 1996) and 3rd most common 
cause of death worldwide by 2020 (Lopez 1998).  
 
Although COPD has been considered primarily in terms of its effects on lung parenchyma 
and airways, attention is now being focused on its systemic effects (American Thoracic 
Society/European Respiratory Society 1999; Celli 2004a). Increasing evidence suggests a 
multisystem disorder encompassing skeletal muscle dysfunction, cardiac disease, 
osteoporosis, metabolic disturbance, neurological impairment and systemic inflammation 
(Bolton 2004; Hopkinson 2004a; Sin 2006; Baker 2009; Barnes 2009). An important 
illustration of this is the role of pulmonary rehabilitation, which improves health status 
and exercise capacity without influencing lung function in COPD patients (Lacasse 2006; 
Dodd 2011).  
 
Skeletal muscle impairment in particular, represents a key component of the systemic co-
morbidities in COPD with loss of skeletal muscle bulk and strength now recognised as 
important predictors of mortality in this patient group (Marquis 2002; Swallow 2007a). 
The mechanisms involved in the development of muscle weakness are likely to be multi-
factorial with systemic factors including inflammation and oxidative stress (Shrikrishna 
2009) thought to interact with local factors such as muscle inactivity (Hopkinson 2010).  A 
greater understanding of the key mechanisms involved in skeletal muscle dysfunction may 
provide a target area for novel interventions, as an adjunct to pulmonary rehabilitation, 
which remains the mainstay of current therapy.   
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1.2  Hypotheses  
 
 
The work contained in this thesis aims to address the following questions of significance to 
patients with COPD: 
 
(1)  Does quadriceps wasting occur in patients with mild as well as advanced COPD, 
when compared to healthy age-matched controls, and is this associated with their level of 
daily physical activity? 
 
(2) Does angiotensin-converting enzyme (ACE) inhibition have a beneficial effect on 
quadriceps endurance, strength and cross-sectional area in COPD patients with quadriceps 
weakness? 
 
(3) Does ACE-inhibition influence the atrogene mediated pathway of muscle atrophy 
in the quadriceps of patients with COPD and is there an effect on serum inflammatory 
markers? 
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1.3 Skeletal muscle anatomy and physiology 
 
 
1.3.1 Muscle structure and fibre classification  
 
 
Striated muscle cells are found in two tissues in vertebrates - skeletal and cardiac muscle. 
Skeletal muscles, under the control of the somatic nervous system, are able to perform 
voluntary movements and have varying slow twitch and fast twitch contractile properties. 
Three skeletal muscle fibre types exist in humans – Type I, Type IIa and Type IIx - based on 
expression of the predominant myosin heavy chain (MHC) isoforms. Type I are slow-
twitch, aerobic fibres with increased oxidative enzyme expression, mitochondrial content 
and capillary supply. Type IIa are fast-twitch fibres but with a similar oxidative profile to 
the type I fibres. Type IIx are fast-twitch, anaerobic fibres with a high glycolytic enzyme 
expression (Prince 1981). 
 
Skeletal muscle fibres are large multinucleated cells surrounded by an electrically polarised 
membrane – the sarcolemma. The muscle fibres are grouped in a connective tissue sheath 
(perimysium) and arranged in bundles known as fascicles. These fascicles are grouped in 
further connective tissue (epimysium) to form the whole muscle. An individual muscle 
fibre contains thousands of myofibrils or ‘muscle threads’ arranged in parallel, each of 
which contain a series of sarcomeres which are the functional unit of contraction. 
Importantly, in a mature muscle, the number of these sarcomeres can alter with the 
appropriate stimulus thereby allowing muscles to adapt (Lieber 2000).  
 
A sarcomere is made up of two types of contractile protein filaments - thick filaments 
composed largely of the protein myosin and thin filaments containing three proteins - 
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actin as the predominant one, tropomyosin and troponin. The thick filaments correspond 
to the A band of the myofibril, overlapped on either end with the thin filaments that form 
the I band. A sheet of alpha-actinin in the centre of the I band, known as the Z-disc, 
anchors the thin filaments and the region between two adjacent Z-discs represents an 
individual sarcomere. Cytoskeletal crosslinking proteins including myomesin and titin 
contribute to elasticity and complete the highly ordered structure as shown in figure 1.1. 
 
 
 
 
Figure 1.1: Striated muscle structure  
Adapted from (Braun 2011) 
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1.3.2 Muscle contractile mechanism 
 
 
There are three key events in skeletal muscle contraction. The first is electrical excitation 
of the muscle fibre, followed by excitation-contraction coupling and finally fibre 
contraction based on the sliding filament mechanism originally described by Huxley in 
1971 (Huxley 1971). The fibres are arranged into motor units each innervated by a single 
motor neuron. Stimulation from the motor neuron results in depolarisation of the 
sarcolemma and after reaching a threshold, an action potential is generated. This electrical 
excitation causes calcium ions to be released from the terminal cisternae of the 
sarcoplasmic reticulum. These calcium ions cause a conformational change in troponin 
subunits attached to the actin filament. At rest, tropomyosin wraps around the actin 
filaments, blocking myosin binding sites, however with this change in shape, the 
tropomyosin complex moves deeper into a groove of the actin molecule thereby exposing 
the myosin-binding sites. This allows the process of muscle fibre contraction to begin 
where actin filaments slide past the myosin filaments shortening the sarcomere length. 
The hydrolysis of ATP to ADP and inorganic phosphate energises the myosin heads 
allowing them to bind to actin forming cross-bridges. This formation then releases 
inorganic phosphate and triggers the power stroke where the myosin head rotates and 
pulls the actin filament towards the centre of the sarcomere. ATP then binds to the myosin 
head releasing it from actin and the contraction cycle can start again. When intracellular 
calcium levels fall, the myosin-binding sites on actin are blocked by the tropomyosin 
complex and the muscle fibre returns to its relaxed state. The force produced is defined by 
sarcomere length (i.e. myofilament overlap). At an optimal length when crossbridge 
interactions are maximal, the muscle produces a maximum force. 
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1.4 Importance of Skeletal Muscle Impairment in COPD 
 
 
Skeletal muscle impairment can be considered in terms of muscle bulk and muscle 
function though these are of course related. Weight loss has long been recognised as a 
feature of COPD (Fowler 1898) occurring in 15% of mild and 25% of moderate to severe 
COPD patients (Wilson 1989; Schols 1993; Engelen 1994) and is associated with a poor 
prognosis (Boushy 1964; Vandenbergh 1967; Gray-Donald 1996; Schols 1998; Landbo 
1999; Prescott 2002; Chailleux 2003; Cano 2004; Celli 2004b; Marti 2006).  
 
Different patterns of weight loss occur depending on whether there is a loss of fat mass, 
fat free mass (FFM) or both (Schols 1993). It is clear that preservation of FFM is more 
important than body weight, as normal weight patients with nutritional depletion (fat free 
mass index <15kgm-2 for women or <16kgm-2 for men (Baarends 1997)) are more disabled 
than underweight patients with a preserved FFM (Shoup 1997; Mostert 2000). Skeletal 
muscle is a major component of FFM and FFM depletion in COPD is associated with 
reduced exercise performance, increased dyspnoea and impaired health related quality of 
life (Hamilton 1995; Gosselink 1996; Bernard 1998).  Leg discomfort makes a significant 
contribution to exercise limitation in patients with COPD (Killian 1992; Man 2003a) and 
where low frequency quadriceps fatigue occurs after exercise, bronchodilation has been 
found not to increase exercise capacity (Saey 2003). 
 
Skeletal muscle weakness does not occur equally in the upper versus lower limbs. The 
same is also true when comparing limb and respiratory muscles with different muscle 
compartments responding to the particular demands placed on them (Gea 2001a). The 
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quadriceps is one of the main muscles of ambulation and has been the focus of much of 
the work around skeletal muscle impairment in COPD. In moderate to severe COPD the 
mean reduction in quadriceps strength is approximately 30% (Bernard 1998; Man 2003b; 
Hopkinson 2004b; Man 2005) with significant weakness present in about 30% of patients 
(Swallow 2007a). Quadriceps weakness has been shown to be related to impaired quality 
of life (Simpson 1992), exercise limitation (Gosselink 1996) and increased health care 
utilisation (Decramer 1997), and predicts survival more powerfully than FFM or forced 
expiratory volume in 1 second (FEV1) (Swallow 2007a). A reduction in quadriceps 
endurance has also been demonstrated in COPD using both volitional and non-volitional 
techniques of assessment (Coronell 2004; Swallow 2007b).  
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1.5  Mechanisms of Skeletal Muscle Dysfunction in COPD 
 
 
Skeletal muscle atrophy and hypertrophy can be influenced by a number of processes that 
are relevant to patients with COPD. A complex interplay of factors including systemic 
inflammation, oxidative stress and muscle disuse are thought to have a role. Some of the 
medications used to treat COPD, particularly corticosteroids, may also have a deleterious 
effect. In addition, genetic susceptibility (Hopkinson 2004b; Hopkinson 2006; Hopkinson 
2008) might explain why some COPD patients demonstrate greater peripheral weakness 
than others.   
 
 
1.5.1 Disuse 
 
 
Patients with COPD are breathless when they exercise and this is reflected in a reduction 
in physical activity which may be very pronounced (Pitta 2005). Quadriceps weakness can 
occur with relatively brief periods of bed rest (10 days) in healthy elderly subjects 
(Kortebein 2007) or indeed other medical conditions (Harris 2001) and has been described 
within a week of  hospital admissions with COPD (Spruit 2003). Following hospitalisation 
for an acute exacerbation, COPD patients have been shown to have reduced physical 
activity which can continue for several weeks (Pitta 2006). Furthermore, early pulmonary 
rehabilitation in the recovery period after discharge, following admission with an acute 
exacerbation of COPD, leads to significant improvements in functional capacity at 3 
months (Man 2004).  Weakness in patients with stable COPD is most pronounced in the 
locomotor muscles (Man 2003b; Man 2005) and at biopsy a  classic disuse pattern of 
change is observed in the quadriceps with a shift towards a preponderance of ‘fast’ Type II 
fibres (Jakobsson 1990; Gosker 2003; Gosker 2007), reduced capillarity (Jobin 1998) and a 
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reduced oxidative capacity (Jakobsson 1990). This pattern is not seen in the deltoid muscle 
(Gea 2001b) and the reverse effect, a shift towards a preponderance of slow fibres, is seen 
in the diaphragm which exhibits increased activity in COPD patients (Levine 1997).  
 
 
1.5.2 Systemic Inflammation and Oxidative Stress 
 
 
Systemic inflammation is present in patients with COPD as evidenced by increased levels 
of tumour necrosis factor-α (TNF-α) and C-reactive protein (CRP) (Gan 2004). However, 
although early data supported a role for increased serum levels of cytokines such as TNF-α 
in muscle wasting in severe COPD (Di Francia 1994), a review incorporating the more 
recent studies of circulating TNF-α levels has concluded that there is no difference in TNF- 
α between cachectic and non-cachectic COPD patient groups (Wagner 2008). The 
diminished role for TNF-α in COPD peripheral muscle dysfunction has been supported by a 
study identifying that levels of quadriceps muscle TNF-α actually fall with decreasing 
strength (Barreiro 2008).  This study also found no difference in IL-6, interferon-gamma or 
TGF-β protein expression in muscle between COPD patients and controls suggesting that 
the quadriceps muscle does not exhibit a pro-inflammatory environment in patients with 
severe COPD. The latter study did however, identify markers of quadriceps muscle 
oxidative stress in this patient group and in support of this, depletion of the reduced form 
of glutathione levels has also been observed in COPD patients when compared to controls 
(Rabinovich 2006). It is well established that free radicals produced by oxidative stress are 
capable of causing tissue damage and such radicals may well have a role in the muscle 
atrophy seen in COPD (Couillard 2005). In addition, it has been demonstrated that chronic 
endurance exercise leads to nitrosative stress in the quadriceps of severe COPD patients 
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(Barreiro 2009). Interestingly, recent work indicates that COPD patients exhibit different 
quadriceps muscle gene expression patterns in response to training when compared to 
controls (Radom-Aizik 2007), although this study had relatively few participants. 
Nevertheless, it was reported that oxidative stress gene pathways were more highly 
expressed in COPD patients than controls after training. Further work is needed to 
establish the role of oxidative stress in COPD and to investigate if attenuation of these 
pathways can enhance training responses in this patient group.  
 
 
1.5.3 Corticosteroids 
 
 
Steroid induced myopathy classically affects the proximal muscles with atrophy of fast 
twitch fibres and frank myopathy has been described as a complication of corticosteroid 
use in COPD (Decramer 1996). However, interpretation is confounded by the effects of 
frequent exacerbations which are the classical indication for steroid therapy in this patient 
group. It has been shown that a two week course of prednisolone in stable COPD patients 
had no effect on skeletal muscle parameters (Hopkinson 2004c) and cross-sectional 
studies have not demonstrated a link between muscle depletion and steroid use in COPD 
(Schols 1993; Hopkinson 2004b) although there are other reasons to avoid chronic steroid 
therapy (Schols 2001). 
 
 
1.5.4 Role of acute exacerbations 
 
 
In addition to the emphysematous or airways predominant groups, frequent exacerbators 
are a key clinical phenotype in COPD (Hogg 2004; Han 2010; de Oca 2012). When COPD 
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patients are hospitalised for an exacerbation, quadriceps strength falls by a further 5%, 
and recovery of baseline strength is not seen in all patients (Jakobsson 1990).  
Consequently, reduced FFM is associated with exacerbation frequency both in a cross-
sectional study (Hopkinson 2004b) and with decline in FFM prospectively (Hopkinson 
2007).  The mechanism for this is likely to be multifactorial as acute exacerbations 
integrate many of the factors that are thought to contribute to muscle weakness including 
inflammation, immobility, negative nitrogen balance, and the administration of 
corticosteroids.  
 
 
1.5.5 Molecular mechanisms 
 
 
The molecular biology underlying the skeletal muscle dysfunction observed in COPD 
remains to be determined. A key catabolic pathway involved in skeletal muscle atrophy is 
mediated through two ubiquitin ligases, the atrogenes atrogin-1 and muscle RING finger 
protein-1 (MuRF-1). These ligases are muscle specific enzymes which have been shown in 
murine models to mediate protein degradation and hence muscle wasting as part of the 
ubiquitin proteasome pathway (Ottenheijm 2008). There is evidence of increased 
expression of MuRF-1 and atrogin-1 in the quadriceps muscle of COPD patients in 
comparison to healthy age-matched controls (Doucet 2007).  In addition, this study 
showed that the Forkhead box class O (FoxO) of transcription factors, which induce MuRF-
1 and atrogin-1, were present at an increased protein concentration in the quadriceps of 
COPD patients compared to the healthy subjects.  
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The anabolic hormone, insulin-like growth factor-1 (IGF-1), acts through the 
phosphoinositide 3-kinase (PI3K)/AKT pathway with IGF-1 receptor activation leading to 
AKT phosphorylation. This disables FoxO transcription factors and prevents expression of 
the atrogenes, thereby inhibiting muscle catabolism (Sandri 2006). In addition, AKT 
phosphorylation activates the mammalian target of rapamycin pathway (mTOR) which  
upregulates p70S6K (70kDa ribosomal S6 protein kinase) (Rommel 2001) and inhibits 4EBP-1 
(eukaryotic initiation factor 4E binding protein-1) (Hara 1997), thereby promoting protein 
synthesis. Phosphorylated AKT can also act independently of mTOR to inhibit GSK-3β 
(glycogen synthase kinase-3β), a repressor of protein synthesis (Cross 1995; Vyas 2002). 
 
It has been shown that IGF-1 levels are reduced in COPD patients in the stable state 
compared to healthy controls (Crul 2007).  Furthermore, in COPD patients undergoing 
pulmonary rehabilitation, increases in exercise capacity and fibre size are associated with 
upregulation of IGF-1 and a splice variant of IGF-1 (mechano growth factor, MGF) 
(Vogiatzis 2007).  Interestingly, MGF is specifically produced in response to mechanical 
stretch and leads to muscle hypertrophy and satellite cell activation (Goldspink 2003).  
 
Local IGF-1 expression also down regulates NF-κB and  pro-inflammatory cytokines 
including TNF- α, IL1-B, high mobility group protein-1 (HMGB1) and macrophage migration 
inhibitory factor (MIF) (Pelosi 2007).  NF-κB acts as a key downstream mediator of the 
inflammatory cytokine cascade, as well as being activated by other triggers including 
inactivity (Hunter 2002). NF-κB is controlled via the IKK (inhibitor of NF-κB kinase) complex 
and in murine studies, targeted deletion of this complex suppressed NF-κB activation and 
led to a shift in muscle fibre distribution towards a Type I phenotype and improved muscle 
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force (Mourkioti 2006).  In addition, NF-κB expression has been shown in transgenic mice 
to be associated with over expression of MuRF-1 leading to muscle atrophy (Cai 2004). As 
NF-κB activation occurs in the skeletal muscle of COPD patients with low body weight 
(Agusti 2004)  this transcription factor may have an influence in the muscle atrophy 
observed in this patient group.  
 
Interestingly NF-κB has also been shown to inhibit a key myogenic regulatory factor, MyoD 
(Langen 2004).  MyoD is involved in the control of myogenic satellite cells which mediate 
muscle repair and regeneration (Megeney 1996; Hawke 2001)  and hence its inhibition can 
prevent a response to muscle injury. Myostatin, a member of the TGF-β superfamily, is 
also a negative regulatory factor of myogenic satellite cells. Through inhibition of MyoD, 
myostatin suppresses satellite cell differentiation and muscle repair (Joulia 2003). A role 
for myostatin in the skeletal muscle dysfunction observed in COPD comes from a cross-
sectional study by Plant et al, who found increased expression of myostatin mRNA in the 
quadriceps of cachectic COPD patients compared to healthy controls (Plant 2010). In 
addition, levels of quadriceps myostatin mRNA expression have been shown to negatively 
correlate with quadriceps strength, six minute walk distance (6MWD), locomotion time as 
a measure of daily physical activity and quadriceps endurance assessed by repetitive 
magnetic stimulation in 18 COPD patients (Man 2010). Further work is needed to establish 
if myostatin has a key role in driving the reduction in strength, exercise capacity and 
activity seen in these patients.  
 
Peroxisome proliferator-activated receptors (PPARs) may have an important role in the 
maintenance of muscle mass in COPD (Sathyapala 2007). These transcriptional co-factors 
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have a key regulatory role in skeletal muscle phenotype and angiogenesis (Arany 2008).  
PPARs mediate Type II (fast twitch, anaerobic) to Type I (slow twitch, aerobic) fibre shift 
and regulate mitochondrial activity as well as muscle oxidative status (Luquet 2003). PPAR 
gamma coactivator 1α (PGC-1α) expression in transgenic mice has been shown to promote 
a type I oxidative phenotype possibly through co-activation of myocyte enhancer factor-2 
(MEF-2) (Lin 2002). PGC-1α suppresses the activity of FoxO to reduce the expression of the 
ubiquitin ligases involved in muscle atrophy (Sandri 2006).  In addition it has been shown 
that PGC-1α knockout mice have reduced skeletal muscle vascular endothelial growth 
factor (VEGF) levels and reduced capillary/fibre ratio (Arany 2008; Leick 2009). Remels et 
al have shown that PPAR-delta protein content is decreased in the skeletal muscle of COPD 
patients with a cachectic COPD subgroup also found to have decreased PPAR-alpha mRNA 
expression (Remels 2007). Further work is needed to establish the importance of reduced 
levels of PPAR expression in the skeletal muscle abnormalities in COPD. Figure 1.2 shows 
some of the key molecular pathways of muscle wasting outlined above. 
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Figure 1.2: Molecular pathways of skeletal muscle wasting  
Adapted from (Glass 2005) & (Man 2009). (IGF-1, insulin-like growth factor 1; IGF1R, insulin-
like growth factor 1 receptor; PI3K, phosphoinositide 3-kinase; GSK3β, glycogen synthase 
kinase 3β; mTOR, mammalian target of rapamycin; eIF2B, eukaryotic initiation factor 2B; 
p70S6K, 70kDa ribosomal S6 protein kinase; E4-BP1, eukaryotic initiation factor 4E-binding 
protein-1; FoxO, forkhead box O; PPAR, peroxisome-proliferator-activated receptor; PGC-1α, 
PPAR-y coactivator-1α; TNF-α, tumour necrosis factor-α; IL-1, interleukin-1; IL-6, interleukin-6; 
IKK, inhibitor of NF-κB kinase; NF-κB, nuclear factor kappa B; MuRF-1, muscle ring finger 
protein-1)  
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1.6 The Renin-Angiotensin System  
 
 
1.6.1 The Role of the Angiotensin-Converting Enzyme 
 
 
A local renin-angiotensin system (RAS) exists in many human tissues including lung and 
skeletal muscle. Angiotensin-converting enzyme (ACE) is a zinc metallo-peptidase present 
in the circulating plasma and highly expressed in lung capillary blood vessels (Studdy 
1983). Angiotensin II receptors are expressed in the lungs (Kakar 1992) and, importantly, 
ACE expression is also evident on the membrane of vascular endothelial cells in muscle 
(Schaufelberger 1998). The RAS, as illustrated in figure 1.3, is mediated initially by renin 
which cleaves angiotensinogen to produce angiotensin I. ACE then catalyses the 
conversion of angiotensin I to angiotensin II, as well as the breakdown of vasoactive kinins. 
Angiotensin II is a potent vasoconstrictor acting directly on smooth muscle cells but it also 
stimulates sympathetic nerve terminals to release the vasoconstrictor norepinephrine and 
facilitates aldosterone secretion from the adrenal cortex, via angiotensin II type 1 (AT1) 
receptors. This enables ACE to exert an influence on salt/water retention and vascular 
tone. In addition, these effects are enhanced by the ACE dependent degradation of 
bradykinin, which when active, can mediate the release of the vasodilator, nitric oxide and 
prostaglandins (Carter 2005).  Angiotensin II type 2 (AT2) receptors oppose some of the 
type I receptor mediated vasoconstrictor effects, through local vasodilation. The human 
lung expresses both angiotensin II receptor subtypes, whereas only the type 1 receptor is 
expressed in adult human skeletal muscle (Malendowicz 2000).  
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Figure 1.3: The Renin-Angiotensin system 
Adapted from (Carter 2005) (AT1 receptor, angiotensin II type 1 receptor; AT2 receptor, 
angiotensin II type 2 receptor; BK2 receptor, bradykinin type 2 receptor; ROS, reactive oxygen 
species)  
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1.6.2 The History of ACE-inhibitors 
 
 
ACE inhibitors were initially developed from investigation of the venom of a Brazilian pit 
viper (Bothrops Jararaca) in the late 1960’s (figure 1.4) (Patlak 2004). The Nobel Laureate 
Sir John Vane found that the venom’s effects, including extensive bleeding and a sudden 
fall in blood pressure, occurred through inhibition of ACE activity. This initial source of 
ACE-inhibition highlights the actions of angiotensin II as a vasoconstrictor and growth 
factor to counteract bleeding and initiate vessel wall repair (Ferrari 2009). However, 
although the RAS plays a key role in the stress response, chronic activation of this system 
in humans is thought to influence cardiopulmonary disease and from the initial discovery, 
an oral form of ACE-inhibitor - captopril - was developed for the treatment of 
hypertension. In particular, evidence of an increase in cardiac and peripheral sympathetic 
activation in COPD patients (Volterrani 1994; Heindl 2001) and the interaction between 
this impaired autonomic control and the renin-angiotensin system, termed ‘neurohumoral 
activation’, has led to its implication in the pathogenesis of COPD (Andreas 2005). 
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Figure 1.4: The Brazilian Pit Viper (Bothrops Jaracaca) 
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1.6.3 Renin-angiotensin system and COPD 
 
 
Chronic inflammation of the central and peripheral airways is recognised as a central 
feature of COPD associated with lung remodelling, parenchymal destruction and the 
development of emphysema (Stockley 2009). The RAS is thought to be implicated in the 
pathogenesis of COPD through its involvement in inducing pro-inflammatory mediators in 
the lung (Marshall 2003) (figure 1.5). 
 
 
 
Figure 1.5: Effects of angiotensin II following pulmonary insult 
Adapted from (Marshall 2003) 
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Angiotensin II stimulates the release of cytokines including interleukin 6 (IL-6), monocyte 
chemotactic protein-1 (MCP-1) and TNF- α (Hanif 2010). In particular, alveolar macrophage 
derived MCP-1 has been shown to activate tissue mast cells in response to acute alveolar 
hypoxia thereby triggering systemic inflammation (Chao 2011). Angiotensin II also has an 
immunomodulatory effect on T cell responses which mediate the lung tissue injury 
associated with COPD (Kaparianos 2011). Wong et al have recently shown that alveolar 
type I cells produce pro-inflammatory cytokines and express components of the RAS as 
part of an innate immune response to lung injury (Wong 2012). The study found that this 
cytokine response was mediated by angiotensin II and was inhibited by losartan, an AT1 
receptor antagonist. Interestingly, in COPD patients, Bullock et al found a five to sixfold 
increase in the ratio of AT1 to AT2 receptors in regions of marked fibrosis surrounding 
bronchioles which correlated with the reduction in FEV1 (Bullock 2001). This data supports 
a role for angiotensin II in inducing bronchial constriction via the AT1 receptor (Brown 
2001). The RAS can also generate reactive oxygen species, via the AT1 receptor, promoting 
mitochondrial dysfunction (Benigni 2010) and contributing to the impaired redox signalling 
observed in COPD (Rahman 2006).  
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1.6.4 Renin-angiotensin system and muscle biology 
 
 
Angiotensin II influences the insulin like growth factor system, the ubiquitin-proteasome 
proteolytic pathway and induces the production of pro-inflammatory cytokines in skeletal 
muscle (Cabello-Verrugio 2012) (see figure 1.6). Evidence to suggest influence of the RAS 
on the PI3K/AKT/atrogene pathway comes from animal models where angiotensin II 
administration causes cachexia and muscle specific expression of IGF-1 blocks this 
angiotensin II dependent muscle wasting (Song 2005). Interestingly, the authors of this 
study also postulated that angiotensin II may partially exert its inhibitory action on IGF-1, 
independent of the AT1 receptor, via a glucocorticoid mediated effect. Recent work in 
mice gastrocnemius muscle has also shown angiotensin II transcriptional regulation of 
MuRF-1 and atrogin-1 (Yoshida 2010). This study confirmed that IGF-1 overexpression 
prevented skeletal muscle atrophy and atrogin-1 expression. In addition, dominant 
negative AKT and active FoxO inhibited this IGF-1 mediated effect on angiotensin II action. 
This work highlights the involvement of the ubiquitin degradation pathway in mediating 
the negative effects of angiotensin on skeletal muscle and identifies potential targets for 
intervention. 
 
Insulin-like growth factor-1 receptor (IGF-1R) phosphorylation in human skeletal muscle 
cells has been studied following incubation with telmisartan, valsartan and lisinopril 
(Storka 2008). There was a 2 fold increase in phosphorylation with the ATII receptor 
blockers and a 1.7 fold increase with ACE-inhibition. Phosphorylated AKT levels were also 
increased following incubation with telmisartan, valsartan and lisinopril. The effects 
observed by ATII receptor blockade may be mediated via activation of peroxisome 
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proliferator-activated receptor gamma (PPARy) as IGF-1R phosphorylation was attenuated 
in the presence of a PPARy antagonist.   
 
 
 
Figure 1.6: Postulated actions of the Renin-Angiotensin system in skeletal muscle in COPD 
Adapted from (Hanif 2010). (Ang I, angiotensin I; Ang II, angiotensin II; AT1R, angiotensin II 
type 1 receptor; IGF-1, insulin-like growth factor-1; GLUT 4, glucose transporter 4; NO, nitric 
oxide; TGF-β, transforming growth factor-beta; MAPK, mitogen-activated protein kinase; ROS, 
reactive oxygen species; IL-6, interleukin-6; TNFα, tumour necrosis factor alpha; MCP-1, 
monocyte chemotactic protein-1). Lines ending with a perpendicular segment represent 
inhibitory pathways. 
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Diamond-Stanic et al have recently shown that angiotensin II also inhibits the insulin 
dependent glucose transporter 4 (GLUT4) and decreases phosphorylation of AKT in rat 
soleus skeletal muscle (Diamond-Stanic 2010). The free radical scavenger, superoxide 
dismutase partially reversed the angiotensin II-induced inhibition of glucose transport 
suggesting that reactive oxygen species may have a role in mediating the effect of 
angiotensin on insulin signalling. Further work in this area again using a rat skeletal muscle 
model has shown that angiotensin II induces tyrosine nitration dependent inhibition of 
AKT phosphorylation (Csibi 2010).  Angiotensin II was found to activate the MAP kinases 
(ERK 1 and 2) through a nitration dependent mechanism. In addition this study showed 
that both scavenging of free radicals with myricetin and inhibition of nitric oxide synthase 
restored insulin stimulated AKT phosphorylation and GLUT4 translocation in the presence 
of angiotensin.  This data suggests that oxidative and nitrative stress play a role in 
mediating the angiotensin-induced insulin resistance and atrophy in skeletal muscle.   
 
Bradykinin, via the actions of NO and prostacyclin, can counteract angiotensin II mediated 
effects in skeletal muscle (Hanif 2010). Bradykinin promotes GLUT-4 translocation in 
skeletal muscle, through the actions of nitric oxide (Henriksen 2003). Furthermore, 
absence of the bradykinin receptor 2 gene is associated with insulin resistance in mice 
(Duka 2001). Interestingly, a recent study has found that insulin can stimulate skeletal 
muscle protein synthesis in humans through an indirect mechanism involving endothelium 
dependent NO vasodilation and consequent increased blood flow, capillary recruitment 
and mTOR complex 1 signalling, rather than AKT signalling (Timmerman 2010). Nitric oxide 
also has a key role in inhibiting reactive oxygen species, with fibre type-specific nitric oxide 
shown to protect oxidative myofibres against cachectic stimuli through antioxidant gene 
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expression (Yu 2008). Importantly, enalapril treatment has been shown to reduce 
angiotensin II dependent inflammation and oxidative stress related muscle damage in a 
dystrophic mouse model (Cozzoli 2011). 
 
A key study by Cohn et al has also identified another important target for muscle wasting 
that may be influenced by the RAS (Cohn 2007). The authors found that increased TGF-β 
activity led to a failure of muscle regeneration in fibrillin-1-deficient and dystrophin-
deficient mice. In addition, this study identified that systemic antagonism of TGF-β using 
losartan or a TGF-β neutralising antibody, restored muscle structure and function in both 
mouse models. This highlights a potential role for TGF-β signalling in mediating angiotensin 
II receptor effects in skeletal muscle. Of note, myostatin is both a negative regulator of 
muscle growth, as described previously, and a member of the TGF-β superfamily. In 
cultured rat neonatal cardiomyocytes it has been shown that angiotensin II activates 
myostatin expression via p38 MAP kinase (Wang 2008) and therefore this may also 
represent a target for angiotensin related muscle atrophy.  
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1.6.5 The ACE I/D polymorphism and muscle function 
 
 
The human ACE gene contains a functional polymorphism based on the presence 
(insertion, I) or absence (deletion, D) of a 287 base pair sequence in intron 16 on 
chromosome 17. Therefore three genotypes exist: II, ID, DD and these have an 
approximate distribution of 25, 50 and 25% respectively in a Caucasian population (Jones 
2003). ACE activity is highest in the subjects homozygous for the D allele (DD), is 
intermediate in the ID group and lowest in subjects homozygous for the I allele (II).  
 
A number of clinical studies have investigated a role for ACE expression in COPD by 
stratifying patients by ACE polymorphism. Busquets et al, studied the distribution of the 
ACE polymorphism in 151 male smokers and found that the DD genotype was more 
prevalent in smokers who developed COPD, being associated with a 2-fold increase in the 
risk for COPD (Busquets 2007).  This data provides a genetic link to support the existing 
evidence that ACE activity is both elevated in COPD (Brice 1995) and is associated with 
lung function impairment (Ucar 1997). Kanazawa et al performed right heart 
catheterisation to assess the pulmonary vascular response to exercise challenge in COPD 
patients stratified by ACE genotype (Kanazawa 2000). They found that the DD genotype 
was associated with increased pulmonary artery pressure and pulmonary vascular 
resistance when compared to the II group. In a separate study, COPD patients with a DD 
genotype had a reduced ratio of the change in oxygen delivery to increase in oxygen 
consumption during exercise (Kanazawa 2002), suggesting an impairment in peripheral 
tissue oxygenation. The ACE polymorphism may also be related to low grade systemic 
inflammation in COPD; a study of 72 stable COPD patients observed an increase in serum 
high sensitivity CRP across genotypes DD>ID>II (Tkacova 2007), suggesting that the RAS 
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system may also contribute to the inflammatory response observed in COPD, as previously 
discussed.  
 
The ACE polymorphism also influences muscle phenotype with greater endurance 
observed in patients homozygous for the insertion allele (II) (Myerson 1999; Williams 
2000) and a higher proportion of type I fibres associated with this group (Zhang 2003). In 
contrast, a power-oriented muscle phenotype is seen in subjects with a DD genotype 
(Nazarov 2001; Woods 2001), who interestingly also exhibit greater bradykinin 
degradation in comparison to the II genotype (Brown 1998). Variations in the human ACE 
genotype have been found to influence quadriceps strength in a COPD population 
(Hopkinson 2004b). In a study of 103 stable COPD outpatients, presence of the deletion 
allele (D) of the ACE gene polymorphism was associated with increased quadriceps 
strength, which was not observed in the control group. Bradykinin type 2 receptor (BK(2)R) 
polymorphisms also influence quadriceps muscle strength in COPD patients. It has been 
shown that those patients exhibiting the +9/+9 homozygous genotype, associated with 
lower BK(2)R receptor expression, have a reduced fat free mass and reduced strength 
(Hopkinson 2006). Of note, the ACE polymorphisms have also been shown to interact with 
the effect of vitamin D receptor genotypes on quadriceps strength in COPD (Hopkinson 
2008) highlighting the potential complexity of the influence of genetic susceptibility in the 
muscle phenotype of these patients. 
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1.6.6 Epidemiological studies of ACE-inhibition and muscle function  
 
 
Cross-sectional data from 2,431 hypertensive subjects participating in the Health, Aging 
and Body Composition (Health ABC) study has been used to evaluate if ACE-inhibitor 
treatment is associated with a larger lower extremity muscle mass compared to the use of 
other antihypertensive medications (Di Bari 2004). This analysis found that lower 
extremity muscle mass assessed by DEXA was larger in the ACE-inhibitor group, with a 
trend towards being greater in those ACE-inhibitor users with a longer duration of 
exposure compared to a shorter exposure (as defined by a median split of 2 years).   
 
A key observational study by Onder et al also assessed the relationship between ACE 
inhibitor use and muscle strength in 641 elderly hypertensive women participating in the 
Women’s Health and Aging Study (Onder 2002). They found that at 3 year follow up, 
participants taking an ACE-inhibitor continuously had a lower mean decline in both knee 
extensor muscle strength and walking speed to those using other antihypertensives and 
those not on antihypertensive medication. Intermittent use of ACE-inhibitors was 
associated with a significantly larger decline in walking speed compared to continuous use.  
The study group had poor mobility and no concomitant heart failure at baseline. Of note, 
the group taking an ACE-inhibitor continuously had lower physical activity levels, as 
assessed during a baseline interview, compared to the other groups.   
 
Interestingly, prospective findings from the Women’s Health Initiative Observational Study 
with over 25, 000 participants found that ACE-inhibitors were not significantly associated 
with risk of frailty after 3 years follow-up (Gray 2009). However, if selecting a sub-
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population who were hypertensive on only one or less antihypertensive medication, a 
reduced risk of frailty was observed for those on low and medium equivalent doses of ACE-
inhibitors. 
 
The InCHIANTI study investigated the relationship between ACE-inhibitor treatment and 
IGF-1 serum levels in a large cohort of older subjects (>65 years of age) (Maggio 2006).  
Serum total IGF-1 was significantly higher in participants receiving an ACE-inhibitor (<3 
years duration) having adjusted for confounders in a linear regression analysis. Those 
participants with 3-9 years duration of use of an ACE-inhibitor also had an increase in 
serum IGF-1 but this did not reach statistical significance. A limitation of this study was 
that information on IGF-1 binding proteins was not available and hence details of the IGF-1 
fraction that was biologically active was not known. This study did however highlight IGF-1 
as a potential mechanism through which ACE-inhibition may exert the muscle effects seen 
in observational studies and suggested that clinical doses of ACE-inhibitor could influence 
IGF-1 levels. 
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1.7 Current Treatment Strategies 
 
 
1.7.1 Pulmonary Rehabilitation 
 
 
Exercise training as an essential aspect of multidisciplinary pulmonary rehabilitation has 
been shown to improve exercise capacity (Griffiths 2000; Man 2004) and muscle function 
(Troosters 2000; Casaburi 2001) in COPD patients. Recently, a randomised controlled trial 
has shown that outpatient pulmonary rehabilitation immediately following hospitalisation 
for an acute exacerbation of COPD improves both quadriceps strength and maximal 
walking capacity (ISWT) and reduces the risk of a re-exacerbation requiring hospital 
attendance over a 3 month period (Seymour 2010a). The Grade ‘A’ evidence base for 
exercise as an established therapeutic strategy in these patients has been summarised in 
the American Thoracic Society/European Respiratory Society Statement on Pulmonary 
Rehabilitation (Nici 2006). 
 
 
1.7.2 Nutritional Supplementation 
 
 
Although nutritional depletion is a common feature in COPD there is a limited evidence 
base for nutritional interventions. Creutzberg et al studied the use of oral liquid nutritional 
supplements during an eight week pulmonary rehabilitation course in nutritionally 
depleted patients with COPD (Creutzberg 2003a). They found an increase in FFM, muscle 
strength and exercise performance, with a reduced response observed in patients on oral 
corticosteroid therapy. However it is important to note that other studies have not shown 
similar effects and a Cochrane review concluded that two weeks of calorie 
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supplementation did not significantly affect exercise capacity, lung function or 
anthropometric measures (Ferreira 2005). Creatine supplementation has also been tried 
as an adjunct to rehabilitation and although effective in restoring muscle creatine levels, it 
does not improve function, probably because this is not a factor limiting exercise in COPD 
patients (Deacon 2008). Further work is needed to explore the potential benefits of 
nutrition in COPD which may be confined to particular patient subgroups. 
 
 
1.7.3 Hormonal Treatments 
 
 
Casaburi et al conducted a placebo-controlled trial showing an increase in leg strength and 
leg lean mass in a study using a ten week course of testosterone combined with leg 
resistance training, in male patients with COPD (Casaburi 2004). Further muscle biopsy 
studies in this cohort have suggested that the muscle IGF system may play a role in the 
mechanism underlying this response (Lewis 2007). Other work in this area has shown more 
varied outcomes. A placebo controlled trial using growth hormone in COPD, found an 
increase in lean body mass, but did not show a change in peripheral muscle strength or 
exercise capacity (Burdet 1997). In addition, the use of anabolic steroids like nandrolone, 
was not found to improve skeletal muscle strength in COPD patients (Creutzberg 2003b).  
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1.7.4 Electrical Stimulation 
 
 
The use of electrical stimulation of skeletal muscle is under evaluation as a potential 
training technique for patients who cannot exercise conventionally due to breathlessness. 
A study assessing the effects of six weeks of electrical stimulation on the quadriceps 
muscle of nine COPD patients found an increase in strength and shuttle walk distance, 
when compared to controls (Bourjeily-Habr 2002). In addition, a small randomised 
controlled trial has compared quadriceps electrical stimulation and rehabilitation, with 
rehabilitation alone, in severe COPD patients following ITU admission (Vivodtzev 2006). A 
significant increase in muscle strength and six minute walk distance was observed in the 
electrical stimulation intervention group. A recent systematic review of the evidence on 
the effects neuromuscular electrical stimulation in patients with chronic heart failure or 
COPD (Sillen 2009), has identified improvements in muscle strength and exercise capacity 
in a number of studies using this technique. Larger prospective randomised controlled 
trials are therefore needed to establish the role of electrical stimulation as a potential 
training strategy.   
 
 
1.7.5 Antioxidant Medication 
 
 
Koechlin et al, have studied the potential therapeutic benefits of the antioxidant, N-
acetylcysteine (NAC), in severe COPD patients. They found that NAC improved quadriceps 
endurance and prevented exercise induced oxidative stress (Koechlin 2004). More 
recently, the antioxidant properties of pressurised whey have been investigated in a 
randomised double-blind placebo controlled trial of 22 COPD patients (Laviolette 2010). 
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This study found an improvement in work rate on a cycle endurance test in the whey 
group compared to placebo suggesting a potential effect of increased glutathione levels, 
although systemic levels were not significantly changed from the placebo group. Further 
work is required in larger study populations to establish the full potential of these 
therapies in the muscle dysfunction observed in COPD patients. 
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1.8 Research questions 
 
 
This thesis aims to investigate skeletal muscle dysfunction in patients with COPD. A cross-
sectional study is undertaken to assess whether quadriceps wasting, measured using 
ultrasound measurement of rectus femoris, exists in mild as well as advanced disease 
compared to healthy age-matched controls. The influence of factors such as physical 
inactivity on quadriceps muscle wasting in these patients is also discussed.  
 
A double-blind randomised placebo controlled trial is then conducted to investigate 
whether targeting the renin-angiotensin system through angiotensin converting enzyme 
(ACE) inhibition could play a role in counteracting muscle dysfunction observed in COPD 
patients. This trial assesses the physiological and molecular effects of the ACE-inhibitor 
fosinopril, on quadriceps dysfunction in 80 COPD patients with quadriceps weakness. The 
effects of ACE-inhibition on non-volitional quadriceps endurance, quadriceps maximal 
voluntary contraction and mid-thigh computed tomography (CT) cross-sectional area are 
also determined.  
 
Vastus lateralis muscle biopsies taken as part of the ACE-inhibitor trial are then analysed 
for changes in expression of components of the IGF-1/atrogene pathway. The effects on 
serum ACE and systemic inflammation are also assessed, and a post-hoc analysis used to 
investigate stratification by ACE genotype. By establishing the influence of physical 
inactivity and the potential role of ACE inhibition on skeletal muscle impairment in COPD, 
it may be possible to target future therapeutic strategies in this patient group. 
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Chapter 2: Description of Methods 
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2.1 Ethical approval 
 
 
The studies in this thesis were approved by the Ethics Committee of the Royal Brompton 
and Harefield NHS Foundation Trust (07/Q0404/17) and the Joint University College 
London Committees on the Ethics of Human Research (08/H0715/90). All participants 
provided written informed consent and the research was conducted in accordance with 
the declaration of Helsinki.  
 
 
2.2 Subjects studied  
 
 
The patients recruited to studies in this thesis had a COPD diagnosis based on NICE 
guidelines (NICE 2010) (see table 2.1) with severity defined using Global initiative for 
Obstructive Lung Disease (GOLD) stage classification (Rabe 2007). Subjects with a 
significant co-morbidity that limited muscle function or physical activity level were 
excluded. The healthy age-matched control subjects were recruited through local 
advertisements. 
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Table 2.1: GOLD stage classification  
 
   GOLD stage criteria                         
(2008)  
NICE clinical 
guideline (2010) 
 
Post-bronchodilator 
FEV1/FVC 
 
FEV1% 
predicted 
 
Post-                  
bronchodilator 
 
Post-       
bronchodilator 
 
<0.7 
 
≤80% 
 
Stage 1 - Mild 
 
Stage 1 –Mild* 
 
<0.7 50-79% Stage 2 - Moderate Stage 2 - Moderate 
<0.7 30-49% Stage 3 - Severe Stage 3 - Severe 
<0.7 <30% Stage 4 - Very Severe Stage 4 – Very 
Severe 
    
* Symptoms should be present to diagnose COPD in patients with mild airflow obstruction 
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2.3 Body Composition 
 
 
2.3.1 Fat-free mass measurement using single-frequency bio-electrical impedance  
 
 
Body composition was determined by bioelectrical impedance analysis (BodyStat 
QuadScan 4000; BodyStat, Douglas, United Kingdom). This technique uses the electrical 
impedance of body tissues to determine an estimate of total body water, as electricity is 
conducted by dissolved ions. A two-compartment model was used which assumes that 
adipose tissue contains no water and that FFM has a constant hydration of 73% water. 
Single frequency, 50kHz, bioelectrical impedance values were then incorporated into 
regression equations which include height, weight and gender to calculate fat free mass 
(FFM) (Steiner 2002). These disease-specific equations have been validated against other 
techniques for assessing body composition, including deuterium dilution and dual energy 
x-ray absorptiometry (DEXA) (Schols 1991).  
 
Fat free mass equations: 
 
Males: FFM (kg) = 8.383 + [0.465*height2 (cm) / resistance (ohms)] + [0.213*weight (kg)] 
Females: FFM (kg) = 7.61 + [0.474*height2 (cm) / resistance (ohms)] + [0.184*weight (kg)] 
Fat Free Mass Index (FFMI) was calculated by dividing FFM by height in metres squared 
(kg/m2). 
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2.3.2 Multiple-frequency bio-electrical impedance analysis  
 
 
Measurements of multiple-frequency bioelectrical impedance at 5, 50, 100 and 200kHz 
were also made using a BodyStat QuadScan 4000 device. At low frequencies (5kHz) current 
does not penetrate cell membranes however at high frequencies (200kHz) both 
intracellular and extracellular spaces are penetrated. Therefore, the ratio of the 
bioelectrical impedance at these frequencies is thought to give an index of extracellular 
and total body water (Z200/Z5).  
 
 
2.4 Pulmonary Function Testing 
 
 
Pulmonary function testing was undertaken by the Royal Brompton Hospital Lung Function 
Department. Spirometry, plethysmographic lung volumes, carbon monoxide diffusing 
capacity (TLco) (CompactLab system; Jaeger, Wurzburg, Germany) and arterial blood gases 
were determined in accordance with European Respiratory Society (ERS) /American 
Thoracic Society (ATS) recommendations (Macintyre 2005; Miller 2005; Wanger 2005). 
Standardised lung function testing reference equations were based on the European Coal 
and Steel Community (ECSC) reference values (Gibson 1993). 
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2.5 Blood pressure measurement 
 
 
Blood pressure was recorded using an automated blood pressure monitor (Omron M6, 
Omron Healthcare Europe, Hoofddorp, The Netherlands). The subject was rested for at 
least 10 minutes prior to blood pressure measurement. An appropriate cuff size was used 
and the measurement was made in a seated position with the subject’s arm supported at 
the level of the heart. An average of three readings was recorded. Mean arterial pressure 
(MAP) was calculated using the following equation; [MAP ~ diastolic pressure + 
1/3(systolic-diastolic)]. 
 
 
2.6 Quadriceps Muscle Strength 
 
 
The capacity of the muscle to develop maximal force (i.e. muscle strength) can be 
measured by either volitional or non-volitional techniques, using isometric or isokinetic 
methods. Isometric methods involve the static contraction of a muscle without any visible 
movement in the angle of the joint, whereas an isokinetic method involves muscle 
contraction and limb movement through a range of motion at a constant speed. The 
capacity of the muscle to maintain a certain force and to resist fatigue (i.e. muscle 
endurance) can also be measured by volitional or non-volitional techniques. 
 
66 
 
 
2.6.1 Volitional-Quadriceps Maximal Voluntary Contraction 
 
 
A volitional measurement of quadriceps maximum voluntary contraction (QMVC) was 
made using an isometric technique (Edwards 1977). Subjects sat on a modified chair with 
their knee fixed at 90 degrees. An inextensible strap connected the ankle of their 
dominant leg to a strain gauge (see figure 2.1). The signal from the strain gauge was 
amplified and passed to a computer running CHART software (Labchart version 7.1, 
PowerLab Analogue-Digital Converter, AD instruments, Oxfordshire, UK). The subjects 
performed at least 3 sustained maximal isometric quadriceps contractions of between 5 
and 10 seconds duration. Consistent traces within 5% of maximum were obtained. A gap 
of approximately 30 seconds was given between each contraction to allow time to 
recover. Vigorous encouragement was given and the force generated was visible online 
using the CHART software. The QMVC was taken as highest tension sustained for 1 second. 
Quadriceps weakness was defined as QMVC <120% of body mass index (Swallow 2007a). 
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Figure 2.1: Quadriceps maximal isometric voluntary contraction measured using a strain 
gauge. 
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2.6.2 Non-volitional-Supramaximal Magnetic Femoral Nerve Stimulation 
 
 
Twitch response was measured using the technique of supramaximal magnetic stimulation 
of the femoral nerve (Polkey 1996). With this method, after 20 minutes of quadriceps rest, 
unpotentiated twitch quadriceps force (TwQu) was determined using magnetic femoral 
nerve stimulation. Two Magstim 200 monopulse units were discharged using a 70mm 
figure-of-eight coil (figure 2.2) and the mean of at least 5 stimulations at 100% stimulator 
output was taken. A stimulus response curve incorporating a range of stimulator output 
responses (twitch ramp) was used to confirm supramaximality.  
 
 
 
 
Figure 2.2: Quadriceps twitch response measured using magnetic femoral nerve stimulation 
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2.7 Repetitive Magnetic Stimulation 
 
 
2.7.1 Quadriceps Endurance Testing 
 
 
Volitional measures have shown a reduction in muscle endurance in patients with COPD 
(Coronell 2004) but these techniques are dependent on subject motivation and 
coordination. By using a repetitive magnetic nerve stimulator with a flexible mat coil 
wrapped around the quadriceps, it has been possible to show that quadriceps endurance 
assessed non-volitionally is reduced in COPD patients compared to controls (Swallow 
2007b). Subjects received 60 trains of magnetic stimulation, using a Magstim Rapid 2 
stimulator, at a frequency of 30Hz, 2 seconds on, 3 seconds off (see figure 2.3). The % 
stimulator output was determined as that able to produce 20% of the subject’s maximal 
voluntary contraction at baseline. The exponential decay in force produced by consecutive 
stimuli was used to measure endurance half-time. 
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Figure 2.3: Quadriceps endurance measured by repetitive magnetic stimulation with a mat 
coil. 
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2.8 Field Walking Tests 
 
 
2.8.1 Incremental Shuttle Walk Test 
 
 
The incremental shuttle walk test (ISWT) is a standardised field test requiring subjects to 
walk back and forth along a 10m course (Singh 1992). The course is identified by 2 cones, 
9m apart with space to turn (0.5m) at each end. A CD player is used to provide 
standardised incremental audio beeps which dictate the speed at which the subject should 
complete each 10m shuttle during the test. This externally paced incremental format is 
similar to the laboratory incremental exercise test (Palange 2000) and the minimum 
clinically important difference for the ISWT is 47.5m (Singh 2008). The test provides a 
symptom limited assessment of maximal performance and therefore can be used as a 
realistic, objective measurement of disability.  
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2.9 Quadriceps Imaging 
 
 
2.9.1 Ultrasound Rectus Femoris Cross-sectional area  
 
 
Measurement of quadriceps rectus femoris cross-sectional area was made by ultrasound 
(Seymour 2009) (see figure 2.4), based on a method originally devised by de Bruin (de 
Bruin 1997). B-mode ultrasonography was used with an 8MHz 7cm linear signal transducer 
array (PLF 805 ST, Toshiba Medical Systems, Crawley, UK). The patient was positioned 
supine with their rested leg supported in passive extension. An anatomical landmark was 
found at three-fifths distance along a line from the anterior superior iliac spine to the 
superior patella border. Ultrasound contact gel was applied to provide an adequate 
interface between the transducer probe and the skin to minimise any soft tissue pressure 
distortion. The transducer was positioned in the transverse plane and orientated so that 
the entire rectus femoris cross-sectional area could be visualised onscreen. Scanning depth 
was set to where the femur could also be viewed for orientation. Slow contraction-
relaxation manoeuvres were used to aid delineation of the muscle septa. The image was 
then frozen and the inner echogenic line representing the fascia around the rectus femoris 
was outlined manually by the operator. Rectus femoris cross-sectional area was calculated 
using a planimetric technique (Nemio, Toshiba Medical Systems) and the average of three 
consecutive measurements was taken.  
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Figure 2.4: Ultrasound of the quadriceps  
(RF, rectus femoris; VL, vastus lateralis; VM, vastus medialis; VI, vastus intermedius). 
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2.8.2 Mid-thigh Computed Tomography Cross-sectional area 
 
 
Measurement of mid-thigh cross-sectional area was made by CT scan (see figure 2.5), 
based on a previously developed protocol (Marquis 2002). CT was performed on a 64-slice 
CT scanner (Siemens SOMATOM Sensation 64, Erlangen, Germany) with the patient in a 
supine position. A single section of the mid-thigh at a predefined level was obtained using 
the following acquisition parameters: 50mAs, 120kVp. The protocol was modified to 
deliver a reduced amount of radiation per scan. The total radiation dose of two thigh CT 
scans is equivalent to 0.6mSv which is equivalent to 30 chest X-rays (0.02mSv per chest X-
ray) or approximately 3 months of natural background radiation. Images were viewed and 
CT cross-sectional areas calculated using Digital Imaging Communications in Medicine 
viewing software (DicomWorks, version 1.3;http://dicom.online.fr) at standard window 
settings for visualisation of soft tissues (centre 40 HU, window width 380 HU).  
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Figure 2.5: Mid-thigh Computed Tomography image  
(Left image: Rectus femoris CSA;  Rt image: Mid-thigh outline, from which femur CSA is 
subtracted to give mid-thigh CSA).   
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2.10 Physical Activity Monitoring 
 
 
2.10.1  Sensewear ProArmband 
 
 
Daily physical activity was recorded using a multisensor biaxial accelerometer armband 
(SenseWear, BodyMedia; Pittsburgh, PA) as previously described by Watz et al (Watz 
2008). Subjects were asked to wear the activity monitor on the upper arm, over the 
triceps, (see figure 2.6) and to only remove the device when bathing or showering. The 
armband incorporates physiological sensors that quantify galvanic skin response, heat flux 
and skin temperature to estimate energy expenditure and has been previously validated 
against indirect calorimetry in COPD patients (Patel 2007; Hill 2010) and against the doubly 
labelled water technique in healthy subjects (St-Onge 2007). The physical activity level 
(PAL) was calculated using total energy expenditure (TEE) and sleep energy expenditure as 
a surrogate for resting energy expenditure (REE) (PAL=TEE/REE). Daily step count and PAL 
were downloaded and analysed using Sensewear professional software version 6.1. 
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Figure 2.6: Sensewear Pro Armband 
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2.11 Patient Questionnaires 
 
 
2.11.1  St George’s Respiratory Questionnaire 
 
 
This standardised 76-item self-complete questionnaire (Jones 1992) allows a total score to 
be calculated based on three component scores; symptoms, activity and impacts on daily 
life. The scores all range from 0-100 with a higher number indicating a worse health 
related quality of life. A change of 4 points is considered clinically significant. The 
questionnaire provides a validated measurement of impaired health, in conditions of 
chronic airflow limitation including COPD.  
 
 
2.11.2  COPD Assessment Test  
 
 
This short, self-complete questionnaire has been recently developed as a standardised 
measure of COPD health status (Jones 2009). The questionnaire contains 8 items, each 
with a score ranging from 0-5, which are then added to give a score from 0-40 (figure 2.7). 
A higher score represents worse health and a change of 2.5 points is considered likely to 
represent a clinically important difference. The questionnaire is simple to complete and 
provides a user-friendly assessment of health related quality of life in COPD.  
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Figure 2.7: COPD Assessment Test (CAT)  
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2.12 Quadriceps Muscle Biopsy  
 
 
2.12.1  Bergstrom Technique 
 
 
Muscle biopsies were taken from the vastus lateralis muscle using a Bergstrom needle 
biopsy technique (see figure 2.8) (Bergstrom 1975). The subject reclined on a couch in a 
lateral position with the knee supported by a pillow. The correct anatomical position was 
identified at the midpoint between the anterior superior iliac spine and the patella. The 
biopsy site was cleaned with a chloroprep solution and then the skin anaesthetised with 
10ml of Lignocaine 2%. After suitable anaesthesia, an incision of approximately 1cm was 
made in the skin and a Bergstrom biopsy needle used to take small samples of muscle. A 
second operator attached a 50ml syringe to the needle to provide suction during the 
biopsy. Following the procedure, steristrips were applied to the incision site. This muscle 
biopsy technique is minimally invasive and subjects can mobilise freely following the 
procedure.  A pea sized (approximately 60mg) muscle biopsy sample was snap frozen in 
liquid nitrogen and then stored at -80 OC prior to mRNA and protein analysis.  
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Figure 2.8: Bergstrom vastus lateralis muscle biopsy 
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2.12.2  RNA extraction and cDNA synthesis  
 
 
For RNA extraction, muscle samples were homogenised in TRIzol reagent (Sigma, UK) using 
1.4mm ceramic beaded tubes (Stretton Scientific, UK) and a Precellys 24 homogeniser 
(Peqlab, Erlangen, Germany). The protocol was 2x10 second cycles at 5500rpm with a 5 
second pause. The samples were then centrifuged at 8000rpm for 3 minutes, with the 
resulting supernatant transferred to 1.5ml microcentrifuge tubes for extraction. 100µl of 
chloroform was added and the mixture vortexed before being left to settle at room 
temperature for 3 minutes. The sample was centrifuged at 13,000rpm for 15 minutes at 
4˚C so as to separate the mixture into 3 phases with the top transparent phase containing 
the RNA. This top layer was transferred to a separate 1.5ml microcentrifuge tube and 
250µl isopropanol was added to precipitate the RNA. This mixture was left at room 
temperature for 10minutes and then centrifuged at 10,000 x g for 10minutes at 4˚C. The 
resulting RNA pellet was washed twice with 500µl of 75% ethanol. The remaining ethanol 
was removed by re-centrifuging the sample before removing any liquid, and the pellet left 
to dry before finally being re-suspended in 30µl RNase free H20 prior to quantification. 
RNA concentration was quantified by measuring absorption at 260nm with a 
spectrophotometer (Nanodrop ND1000, Wilmington, USA). 
 
First strand cDNA was synthesised using an Omniscript Reverse Transcriptase 200 kit 
(Qiagen). For each sample, 150ng of RNA was added to 11µl of RNase-free water and 
heated to 65˚C for 5 minutes. After 2 minutes on ice, 9µl of a mixture containing 2µl 10x 
Buffer RT, 1µl 5mM dNTPs, 0.5µl random primers, 0.5µl RNase inhibitor, 1µl (0.1M) DTT, 
0.5µl Omniscript reverse transcriptase (Qiagen) and 3.5µl of RNase-free water was added 
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and the samples were incubated at 42˚C for 2 hours.  The samples were then diluted to 
200µl with distilled H2O and stored at -20˚C for subsequent analysis.  
 
 
2.12.3  Primer validation 
 
 
Primers for target genes were validated by Polymerase Chain Reaction (PCR) so as to 
ensure that only the regions of interest were amplified. The reaction mixture contained 
3µl of sample cDNA, 2µl of a forward and reverse primer mix (2pmol/µl), 10µl of 2x SYBR 
green Taq Jump Start mix and 5µl of distilled H2O. The PCR products were analysed by 
electrophoresis on a 2% (w/v) agarose gel containing ethidium bromide to confirm product 
size and exclude primer dimers. 
 
 
2.12.4  Real-Time quantitative Polymerase Chain Reaction (RT-qPCR) 
 
 
Real-time quantitative PCR (RT-qPCR) was performed in duplicate on each sample, testing 
for MuRF-1, atrogin-1, IGF-1, TGF-β and the reference housekeeping gene, human RPLPO. 
A 20µl reaction containing 10µl Fast SYBR Green Master Mix (Applied Biosystems, UK), 5µl 
distilled H20, 2µl of the forward and reverse primer mix (2pmol/µl) and 3µl of the sample, 
was used in 96 well plates (MicroAmp, Fast optical 96 well reaction plate, 0.1 ml, Applied 
Biosystems, UK) with an adhesive plate cover (MicroAmp, Optical adhesive film, Applied 
Biosystems, UK). RT-qPCR reactions were run using a 7500 Fast Real-time PCR System 
(Applied Biosystems, UK), with the following cycle program: 95°C for 5 minutes, then 40 
cycles of 95°C for 10 seconds & 60°C for 30 seconds for annealing and extension. RT-qPCR 
data were analysed using cycle threshold (Ct) values which relate to the number of cycles 
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at which the fluorescence reaches a threshold above a baseline value. The data were then 
normalised to human RPLPO expression as previously described (Ellis 2004), with the 
values log transformed to obtain a normal distribution. 
 
 
2.12.5  Protein extraction and enzyme linked immunosorbent assay (ELISA) 
 
 
For protein extraction, muscle samples were homogenised in lysis buffer (Tris pH 7.4 
(50mM), NaCl (250mM), EDTA (5mM), 1% Nonidet P40 (Roche Applied Science)) 
containing protease and phosphatase inhibitors (Sigma, UK).  Ceramic beaded tubes were 
used with a homogeniser protocol as described above.  A Bradford assay was then used to 
measure protein concentration against BSA standards as per the manufacturer’s 
recommendations. A BioRad microtiter plate reader was used to measure absorbance at 
595nm using Luminex analysis software. To determine levels of phosphorylated 4EBP-1, 
the protein lysate was analysed using an enzyme linked immunosorbent assay (ELISA) kit, 
(Invitrogen) containing a specific 4EBP-1 detection antibody.  The absorbance at 450nm 
was measured using a Bio-Tek plate reader. 
 
 
2.13 Blood Sampling  
 
 
Approximately 20mls of venous blood was taken from subjects and divided into whole 
blood, serum and plasma samples. The whole blood samples were stored at -80˚C for 
subsequent ACE and bradykinin genotyping. Serum and plasma samples were centrifuged 
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and also stored at -80˚C prior to batch analysis for inflammatory cytokines and biological 
markers related to muscle atrophy.  
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2.13.1  ACE and bradykinin genotyping 
 
 
ACE and bradykinin genotyping was conducted by the Department of Cardiovascular 
Genetics, Rayne Institute, University College London. Genomic leukocyte DNA was 
extracted from whole blood by salting out and ACE genotype was determined by PCR with 
amplification using a 3-primer method which included an I-specific oligonucleotide (O'Dell 
1995). The original 2-primer method, where each primer flanked the insertion sequence, 
often preferentially amplified the shorter D allele leading to mistyping of heterozygous 
genotypes as DD. By annealing to the insertion sequence itself, the third primer avoids this 
problem by creating a shorter fragment for the I allele (65 base pairs) compared to the D 
allele (84 base pairs). Primer ratios were 10pmol ACE1 (deletion-specific oligonucleotide), 
2pmol ACE2 (insertion-specific oligonucleotide) and 8pmol ACE3 (common 
oligonucleotide). Each 20µl PCR reaction contained the ACE primers, with 50nM KCl, 
10mM Tris HCl pH 8.3, 1.5mM MgCl2 , 0.2 units of Taq polymerase, overlaid with 20µl 
mineral oil.  Thirty PCR cycles of 95°C for 1 minute, 50°C for 1 minute and 72°C for 5 
minutes were used and the products resolved on a 7.5% polyacrylamide gel stained with 
ethidium bromide. Genotypes were confirmed independently by 2 operators and 
discrepancies resolved through repeat genotyping.  Bradykinin type II receptor genotype 
was determined by PCR using a 2-primer method (forward 5’-TCTGGCTTCTGGGCTCCGAG-
3’ and reverse 5’AGCGGCATGGGCACTTCAGT-3’) with the products resolved on a long gel.  
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2.13.2   Serum analysis 
 
 
Serum analysis was conducted by the King’s Pathology Department, King’s College London. 
A serum cytokine multiplex array was performed by chemiluminescent immunoassay using 
an Evidence Investigator BioChip Analyser (Randox Laboratories, UK) for the quantitative 
detection of interleukin-6, 8, 18 and monocyte chemotactic protein-1. Serum IGF-1, NT-
pro-BNP and hs-CRP were measured by enzyme-linked immunosorbent assay (ELISA) 
(Siemens Healthcare Diagnostics, UK) and serum ACE-activity measured by a kinetic 
enzyme assay (Buhlmann Laboratories AG, Switzerland). 
 
88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Quadriceps Wasting and 
Physical Inactivity in COPD       
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3.1 Introduction 
 
 
3.1.1 Background 
 
 
Skeletal muscle dysfunction is a well recognised extrapulmonary complication of chronic 
obstructive pulmonary disease (COPD) with loss of lean body mass identified as a key 
determinant of disability and an independent predictor of mortality (Schols 2005). In 
particular, reduced quadriceps strength is associated with reduced exercise capacity 
(Gosselink 1996), impaired quality of life (Simpson 1992), increased healthcare use 
(Decramer 1997) and mortality independent of airflow obstruction (Swallow 2007a).  
 
The mechanisms involved in the development of skeletal muscle weakness in COPD are 
likely to be multi-factorial with systemic factors, such as oxidative stress (Barreiro 2010), 
thought to interact with the key local factor of muscle inactivity (Pitta 2005; Watz 2008) 
particularly in the lower limbs (Man 2003b). Objectively measured physical activity has 
been identified as a strong predictor of all-cause mortality in COPD (Waschki 2011), 
highlighting its importance in a ‘downward disease spiral’ where progressive dyspnoea 
leads to reduced exercise capacity with subsequent muscle deconditioning and further 
inactivity (Polkey 2006).  
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3.1.2 Rationale and hypothesis 
 
 
Quadriceps weakness has recently been observed in the absence of severe airflow 
obstruction in COPD (Seymour 2010b), and in addition there is data to suggest a reduction 
in physical activity in GOLD stage I patients (Watz 2009). Despite the potential rationale for 
muscle wasting in mild disease, little data exists on reduced quadriceps bulk in this patient 
group. Mid-thigh cross-sectional area measured by computed tomography (CT) has been 
shown to predict mortality in moderate-severe COPD (Marquis 2002), however the 
ionising radiation exposure makes this method of imaging undesirable particularly in mild 
disease. Magnetic resonance imaging (MRI) has also been used as a thigh muscle imaging 
modality in COPD (Mathur 2008) but the accessibility and expense of this tool prohibit its 
adoption in the wider COPD population.  
 
Ultrasound measurement of rectus femoris cross-sectional area (USRFCSA) is a radiation-
free measure of muscle bulk that relates to quadriceps strength in COPD but is effort 
independent (Seymour 2009). We hypothesised that quadriceps wasting, measured by 
USRFCSA, would be observed in mild as well as advanced COPD compared to healthy age-
matched subjects and that this would correlate with daily physical activity levels. 
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3.2 Methods 
 
 
3.2.1 Study design and participants 
 
 
This cross-sectional study recruited COPD patients from outpatient clinics at the Royal 
Brompton Hospital, King’s College and St Thomas’ Hospitals as well as through public 
spirometry events conducted on World COPD and No-Smoking days. COPD diagnosis was 
consistent with NICE and GOLD criteria as previously described. Subjects within one month 
of an exacerbation or with a significant co-morbidity including cardiac failure, neurological 
disease, malignancy or rheumatoid arthritis were excluded. The healthy age-matched 
controls were recruited by advertisement in local newspapers. 
 
 
3.2.2 Study measurements 
 
 
A clinical history was taken, followed by baseline anthropometric measurements and 
determination of fat-free mass index (FFMI). Heath-related quality of life was assessed 
using the St. George’s Respiratory Questionnaire. Breathlessness was recorded using the 
Medical Research Council (MRC) dyspnoea score. Subjects had full pulmonary function 
tests including measurement of lung volumes and gas transfer. Quadriceps size was 
assessed by ultrasound measurement of rectus femoris cross-sectional area and 
quadriceps strength assessed by maximum voluntary contraction. Daily physical activity 
was recorded using a multisensor armband with step count and physical activity level (PAL) 
measured over six consecutive days incorporating one weekend and four weekdays. A 
valid physical activity assessment was defined as ≥21.5 hours (90%) wearing time a day on 
at least 5 days.  
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3.2.3 Data and statistical analysis 
 
 
Data are presented as mean ± SD, with accompanying p value, and analysis was performed 
using StatView 5.0 (Abacus concepts, Inc., Berkeley, CA, USA). Between group comparisons 
used analysis of variance (ANOVA), with post-hoc correction for more than 2-groups. 
Relationships between USRFCSA, quadriceps strength, FFMI, impedance ratio, daily physical 
activity and pulmonary function were analysed using univariate and multivariate linear 
regression models. Figure construction was performed with GraphPad Prism Version 5.0 
(GraphPad Software, San Diego, California, USA). 
 
 
3.3 Results 
 
 
3.3.1 Participants 
 
 
Two hundred and one subjects, comprising 161 stable COPD patients and 40 healthy age-
matched volunteers, participated in the study.  Baseline characteristics are shown in table 
3.1. Of these, 154 subjects (123 COPD patients and 31 healthy participants) completed a 
valid physical activity assessment. Out of the remaining 47 subjects, 14 did not complete a 
valid period of assessment, 4 subjects declined to participate in this part of the study and 
the remainder were not given an armband for logistical reasons (e.g. armband availability 
and subject’s distance from hospital). In those subjects participating in activity monitoring, 
a valid period of assessment was reached in 92% (154/168). Average wearing time per day 
was 98% and did not significantly differ across groups (see table 3.2).   
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Table 3.1: Baseline characteristics of COPD and control subjects  
 
  
Controls 
(n=40) 
mean (SD) 
 
COPD 
 I 
(n=38) 
 
COPD 
 II 
(n=45) 
 
COPD 
 III 
(n=41) 
 
COPD 
 IV 
(n=37) 
 
 
p 
value 
 
Age (years) 
 
65  
(8) 
 
67  
(9) 
 
67  
(9) 
 
67  
(9) 
 
63  
(8) 
 
0.17 
 
Gender (M/F) 
 
20/20 
 
19/19 
 
22/23 
 
22/19 
 
25/12 
 
0.45 
 
BMI (kg/m2) 
 
25.9  
(3.6) 
 
26.5  
(4.8) 
 
26.6  
(5.9) 
 
25.2  
(4.5) 
 
22.4  
(3.8) 
 
0.0006 
 
FFMI (kg/m2) 
 
17.8  
(2.1) 
 
17.9  
(2) 
 
17.7  
(2.7) 
 
17.6  
(2.2) 
 
16.2  
(1.9) 
 
0.004 
 
Smoking (pack 
years) 
 
9.1  
(14.3) 
 
28.1 
(22.2) 
 
42    
(29.2) 
 
50    
(26.2) 
 
55.5  
(29.3) 
 
<0.0001 
 
Current smokers 
(%) 
 
- 
 
11 
 
 
29 
 
27 
 
14 
 
 
 
0.09 
Outpatients (%) - 47 
 
60 66 89 0.001 
 
Long-acting beta 
agonist (%) 
   
 
- 
 
58 
 
80 
 
85 
 
100 
 
<0.0001 
Long-acting 
anticholinergic 
(%) 
 
- 
 
42 
 
71 
 
83 
 
97 
 
<0.0001 
 
Inhaled 
corticosteroid 
(%) 
 
- 58 78 83 100 <0.0001 
Oral 
corticosteroid   
(% ≥5mg/day) 
- 0 0 0 8 0.02 
 
FEV1 % pred 
 
103.1  
(11.7) 
 
90.8  
(8.8) 
 
63.2  
(8.8) 
 
39.4  
(5.5) 
 
24  
(3.8) 
 
<0.0001 
 
TLco% pred 
 
89.3  
(17.1) 
 
67.5 
(17.8) 
 
58.1  
(14.7) 
 
39.9  
(13.9) 
 
26.6  
(9) 
 
<0.0001 
 
RV%TLC ratio 
 
34  
(4.6) 
 
40.6  
(6.6) 
 
46.6  
(8) 
 
57.9  
(7.5) 
 
64.7  
(6.9) 
 
<0.0001 
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Controls 
(n=40) 
mean (SD) 
 
COPD 
 I 
(n=38) 
 
COPD 
 II 
(n=45) 
 
COPD 
 III 
(n=41) 
 
COPD 
 IV 
(n=37) 
 
 
p 
value 
 
IC 
(litres) 
 
2.8 
(0.7) 
 
2.7 
(0.8) 
 
2.3 
(0.8) 
 
1.9 
(0.6) 
 
1.8 
(0.4) 
 
<0.0001 
 
PaO2 
(kPa) 
 
11.2  
(1.1) 
 
10.6  
(1.5) 
 
10.2  
(1.2) 
 
9.1  
(1.2) 
 
9.1  
(1.3) 
 
<0.0001 
 
PaCO2 
(kPa) 
 
5  
(0.6) 
 
4.7  
(0.5) 
 
5  
(0.4) 
 
5.1  
(0.5) 
 
5.4  
(0.6) 
 
<0.0001 
 
MRC score  
(1-5) 
 
1.1  
(0.3) 
 
1.8 
(0.4) 
 
2.5  
(0.9) 
 
3.1 
(0.9) 
 
3.6  
(0.9) 
 
<0.0001 
 
SGRQ 
(Symptoms) 
 
- 
 
29.4 
(24.8) 
 
49.6 
(22.8) 
 
50 
(23.7) 
 
61.6 
(19.1) 
 
<0.0001 
 
SGRQ  
(Activity) 
 
 
- 
 
34.7  
(25) 
 
58.1 
(23.9) 
 
 
70.1  
(19.4) 
 
84.5 
(11.5) 
 
<0.0001 
SGRQ  
(Impacts) 
- 15.5 
(15.1) 
29.9 
(17.4) 
33.8 
(17.4) 
48.4 
(18.1) 
<0.0001 
 
SGRQ  
(Total) 
 
- 
 
23.1 
(16.8) 
 
41.1  
(17.9) 
 
 
47.6  
(16.4) 
 
 
61.5  
(13.8) 
 
 
<0.0001 
 
 
Abbreviations: BMI - body mass index; FFMI – fat free mass index; FEV1 - forced expiratory 
volume in 1 second; TLco – carbon monoxide diffusing capacity; RV – residual volume; TLC – 
total lung capacity; IC – inspiratory capacity; PaO2 - arterial partial pressure of oxygen; PaCO2 - 
arterial partial pressure of carbon dioxide; SGRQ – St George’s respiratory questionnaire; 
Outpatients – defined as any previous hospital clinic attendance. 
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Table 3.2: Quadriceps and physical activity measurements in COPD and control subjects 
 
  
Controls 
mean  
(SD) 
 
COPD 
I 
 
COPD 
II 
 
COPD 
III 
 
COPD 
IV 
 
p 
Value 
 
 
USRFCSA 
(mm2) 
 
640 
(136) 
 
530 
(116) 
 
511 
(135) 
 
504 
(122) 
 
509 
(122) 
 
<0.0001 
 
QMVC 
(kg) 
 
34.3      
(8.8) 
 
29.6           
(7.2) 
 
27.9            
(7.3) 
 
27.3           
(8.8) 
 
25.3        
(6.8) 
 
<0.0001 
Daily Step 
count 
11735 
(4399) 
7960  
(3430) 
6606   
(3328) 
4010 
(2316) 
2219 
(1157) 
<0.0001 
 
Daily Physical 
Activity Level 
 
1.69 
(0.25) 
 
1.56 
(0.16) 
 
1.47 
(0.16) 
 
1.4 
(0.12) 
 
1.38 
(0.19) 
 
<0.0001 
 
 Armband  
wearing time 
 (hours/day)  
 
 
23.57  
(0.28) 
 
 
23.60  
(0.26) 
 
 
23.64 
 (0.37) 
 
 
23.57 
 (0.52) 
 
 
23.61 
 (0.39) 
 
 
0.95 
 
Z200/Z5 
Impedance 
ratio 
 
0.789 
(0.03) 
 
0.791 
(0.03) 
 
0.806 
(0.03) 
 
0.816 
(0.03) 
 
0.814 
(0.03) 
 
0.0002 
 
Abbreviations: USRFCSA – ultrasound rectus femoris cross-sectional area; QMVC – quadriceps 
maximal voluntary contraction.  
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3.3.2 USRFCSA and quadriceps strength in COPD (Stage I-IV) and healthy subjects 
 
 
USRFCSA and quadriceps strength (QMVC) were reduced in all GOLD stages compared to 
controls (table 3.2, figure 3.1 and figure 3.2). There were no significant differences in 
USRFCSA or QMVC across GOLD stages, except between QMVC in stage I and IV (p<0.02). 
 
 
Figure 3.1: Ultrasound rectus femoris cross-sectional area (USRFCSA) versus GOLD stage in 
COPD patients and healthy controls (ANOVA - no significant difference between I-IV). Cross 
bars represent the standard error of the mean (SEM). 
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Figure 3.2: Quadriceps maximal voluntary contraction (QMVC) versus GOLD stage in COPD 
and healthy controls (ANOVA - no significant difference between GOLD stages, except I and IV; 
p<0.02). Cross bars represent SEM. 
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In COPD patients, FEV1% predicted showed no association with USRFCSA and a weak 
association with QMVC (r=0.2, p=0.03). USRFCSA had a linear relationship with QMVC in 
COPD subjects (r=0.6, p<0.0001) (figure 3.3). QMVC was also significantly associated with 
FFMI (r=0.54, p<0.0001) and the impedance ratio (Z200/Z5) (r=−0.54, p<0.0001) in COPD 
(figure 3.4).  
 
 
 
Figure 3.3: Quadriceps strength (QMVC) versus ultrasound rectus femoris cross-sectional 
area (USRFCSA) in COPD patients (Pearson correlation; r=0.6, p<0.0001). 
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Figure 3.4: Quadriceps strength (QMVC) versus Impedance ratio in COPD patients (Pearson 
correlation; r=−0.54, p<0.0001). 
 
 
A multiple regression model was used to predict USRFCSA in all COPD subjects incorporating 
the significant independent variables from the univariate analysis (see table 3.3). Gender 
(r=0.27, p=0.003), QMVC (r=0.24, p=0.01), residual volume to total lung capacity (RV/TLC) 
ratio (r=−0.28, p=0.01), inspiratory capacity (IC) (r=0.20, p=0.04) and FFMI (r=0.19, p=0.04) 
were retained as independent predictors of USRFCSA (r=0.75, p<0.0001). In a similar 
multiple regression model with QMVC as the dependent variable, only USRFCSA (r=0.24, 
p=0.02) and FFMI (r=0.25, p=0.01) were retained as independent predictors of quadriceps 
strength in COPD (r=0.74, p<0.0001). 
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Table 3.3: Univariate correlates of USRFCSA in all COPD subjects 
 
    USRFCSA (r) p value 
Age −0.20 0.01 
Gender   0.48 <0.0001 
FFMI   0.49 <0.0001 
FEV1 % pred   0.08 0.32 
TLco% pred   0.26 0.001 
RV/TLC ratio −0.22 0.006 
IC   0.44 <0.0001 
QMVC   0.60 <0.0001 
Impedance ratio −0.53 <0.0001 
PAL   0.20 <0.05 
Steps    0.30 0.002 
   
 
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - ultrasound 
rectus femoris cross-sectional area; FEV1 - forced expiratory volume in 1 second; RV – residual 
volume; TLC – total lung capacity; IC – inspiratory capacity; TLco – carbon monoxide diffusing 
capacity; FFMI - fat free mass index; PAL – physical activity level (r and p values derived from 
Pearson’s correlation coefficient).  
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As gender was identified as an independent variable to predict USRFCSA, the COPD and 
healthy subjects were separated into males and females (figure 3.5). In both genders, 
USRFCSA was reduced in all GOLD stages compared to controls and there were no 
significant differences in USRFCSA across GOLD stages. Males (n=108) had a significantly 
greater USRFCSA, compared to females (n=93), 597mm
2 vs 470mm2, (p<0.0001).  
 
 
 
Figure 3.5: Ultrasound rectus femoris cross-sectional area (USRFCSA) in COPD patients and 
healthy controls separated by gender (males - A and females - B; ANOVA - no significant 
difference between stages I-IV. Cross bars represent SEM). 
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3.3.3 Relationship of daily physical activity with GOLD stage and USRFCSA  
 
 
Daily physical activity was significantly reduced in all GOLD stages compared to healthy 
controls (figure 3.6 and figure 3.7).  Mean group differences are shown in table 3.2.  
 
 
Figure 3.6: Daily physical activity (steps) versus GOLD stage in COPD patients and healthy 
controls (ANOVA - significant differences also observed between stages 1,3 & 1,4 p<0.0001; 
2,3 p=0.002; 2,4 p<0.0001 & 3,4 p=0.03). Cross bars represent SEM. 
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Figure 3.7: Physical activity level (PAL) versus GOLD stage in COPD subjects and healthy 
controls (ANOVA - significant differences also observed between stages 1,3 p=0.0006; 1,4 
p=0.0002 & 2,4 p=0.04). Cross bars represent SEM. 
 
104 
 
 
Daily physical activity showed a linear relationship with FEV1% predicted (steps, r=0.6; PAL, 
r=0.4, p<0.0001) and USRFCSA (steps, r=0.3, p=0.002; PAL, r=0.2 p<0.05) in all COPD 
patients. In stage I disease, a multiple linear regression model to predict USRFCSA was used 
incorporating the significant independent variables from the univariate analysis (table 3.4). 
Physical activity level was the only variable retained as an independent predictor of 
USRFCSA in stage I disease (r=0.76, p=0.01). The univariate association between physical 
activity and USRFCSA in stage I disease is shown in fig 3.8. Using a similar regression analysis 
in stage II-IV disease, gender (r=0.29, p=0.01), RV/TLC ratio (r=−0.28, p=0.01) and IC 
(r=0.29, p=0.02) but not physical activity, were retained as independent predictors of 
USRFCSA (r=0.78, p<0.0001). 
 
In a separate multiple linear regression model to predict physical activity in stages II-IV 
COPD, when incorporating the univariate correlates (table 3.5), RV/TLC ratio was retained 
over FEV1% predicted as the only independent variable associated with physical activity 
level (r=−0.23, p=0.03). Using this model in stage I COPD, USRFCSA but not QMVC was 
retained as the only independent correlate with physical activity level (r=0.64, p=0.005).  
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Table 3.4: Univariate correlates of USRFCSA in stage I COPD subjects 
 
 
    USRFCSA (r)  p value 
Age −0.33 0.04 
Gender   0.50   0.001 
FFMI   0.43   0.007 
FEV1 % pred   0.07 0.70 
TLco% pred   0.38 0.03 
RV/TLC ratio −0.42 0.01 
IC   0.41 0.02 
QMVC   0.63   <0.0001 
Impedance ratio −0.64   <0.0001 
PAL   0.70   <0.0001 
Steps    0.53   0.002 
 
 
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - ultrasound 
rectus femoris cross-sectional area; FEV1 - forced expiratory volume in 1 second; RV – residual 
volume; TLC – total lung capacity; IC – inspiratory capacity; TLco – carbon monoxide diffusing 
capacity; FFMI - fat free mass index; PAL – physical activity level. (r and p values derived from 
Pearson’s correlation coefficient).    
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Figure 3.8: Physical activity versus USRFCSA in GOLD stage I COPD subjects  
(Black squares – physical activity level, white squares – step count). 
 
107 
 
 
Table 3.5: Univariate correlates of physical activity in stages II-IV COPD 
 
  Steps (r) p value  PAL (r) p value 
Age  −0.12 0.25 −0.08  0.46 
Gender   0.18 0.10   0.14  0.18 
FFMI   0.19 0.07   0.10  0.40 
USRFCSA   0.24 0.02   0.05  0.70 
FEV1% pred   0.57   <0.0001   0.21 <0.05 
TLco% pred   0.54   <0.0001   0.07   0.50 
RV/TLC ratio −0.53   <0.0001 −0.23   0.03 
IC   0.27 0.01   0.01   0.92 
QMVC   0.22 0.04   0.02   0.82 
Impedance ratio −0.27 0.01 −0.12   0.30 
 
Abbreviations:  QMVC - quadriceps maximum voluntary contraction; USRFCSA - ultrasound 
rectus femoris cross-sectional area; FEV1 - forced expiratory volume in 1 second; RV - residual 
volume; TLC - total lung capacity; IC - inspiratory capacity; TLco - carbon monoxide diffusing 
capacity; FFMI - fat free mass index; PAL - physical activity level. (RV/TLC ratio was the only 
independent predictor of PAL (p=0.03) in stage II-IV COPD; FEV1% pred and TLco% pred were 
independent predictors of step count (p<0.0001). r and p values derived from Pearson’s 
correlation coefficient.) 
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3.3.4 Quadriceps dysfunction and health status in COPD 
 
 
Health status was also assessed using the COPD assessment test (CAT) score in a subset of 
COPD patients (n=91, mean (SD), 66(8) years, FEV1 46(22)% predicted, 56% male). A 
reduced quadriceps strength (QMVC) was associated with a worse health status (CAT score 
>20, n=44: QMVC 23.6 (5.7) kg vs. 27.4 (6.8) kg (p=0.005) (see figure 3.9). In addition, 
reduced quadriceps bulk measured by USRFCSA was also associated with a worse health 
status (USRFCSA 482 (126) mm
2 vs. 539 (120) mm2 (p=0.03) (see figure 3.10) in these 
patients. 
  
 
 
 
Figure 3.9: CAT versus QMVC in COPD subjects 
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Figure 3.10: CAT versus USRFCSA in COPD subjects 
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3.3.5 Ultrasound validity and reproducibility 
 
 
For validation, 80 COPD patients had a mid-thigh CT scan with ultrasound rectus femoris 
cross-sectional area correlating significantly with mid-thigh CTCSA (r=0.7, p<0.0001) and 
rectus femoris CTCSA (r=0.7, p<0.0001). In addition, data on inter-occasion and observer 
variability of the ultrasound measurement is detailed below (see figure 3.11).  
 
 
 
 
 
Figure 3.11: Bland-Altman analysis comparing the rectus femoris cross-sectional area (RFCSA) 
measured by ultrasound on two separate occasions   
(n=21, mean (SD) bias - 0.06 (0.21)cm2 : coefficient of repeatability 0.41cm2), dotted line 
represents 95% limits of agreement -0.47 to +0.36cm2 , index of reliability 0.97. A similar 
analysis was conducted for inter-observer variability (n=10): mean (SD) bias 0.11 (0.29)cm2 : 
coefficient of repeatability 0.57cm2, 95% limits of agreement -0.46 to +0.68cm2, index of 
reliability 0.97. 
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3.4 Discussion 
 
 
3.4.1 Summary of results 
 
 
Using USRFCSA we found quadriceps wasting in mild, as well as advanced COPD judged by 
GOLD stage. A 17% reduction in mean USRFCSA was observed in stage I patients compared 
to a healthy age matched group with a similar whole-body FFMI. The study also identified 
an independent association between physical activity level and USRFCSA in stage I disease, 
with this group significantly less active when compared to healthy subjects. 
 
 
3.4.2 Significance of the findings 
 
 
A recent study incorporating a large UK and Dutch COPD cohort (Seymour 2010b) 
identified a 28% prevalence of quadriceps weakness in Stage I patients and supports our 
contention that reduced quadriceps muscle bulk is present in early disease. The simple and 
effort independent nature of ultrasound makes it an attractive test for detecting patients 
who may benefit from early intervention and avoids the need for strength measurements 
using research based equipment or less reliable portable handheld devices, both of which 
are inherently subject to volitional influence.  Interestingly, in our study, USRFCSA rather 
than quadriceps strength was independently associated with physical activity in stage I 
COPD, implying that this effort independent measure of quadriceps size may be a more 
sensitive parameter for investigating the relationship between lower limb muscle 
dysfunction and physical activity in patients with mild disease. This is particularly 
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important as new COPD phenotypes are established requiring evaluation and as 
therapeutic interventions focus on physical activity promotion (Casaburi 2011). 
 
The finding of reduced daily physical activity in GOLD Stage I COPD when compared to 
healthy subjects is supported by previous data (Watz 2009) showing a reduction in activity 
in Stage I patients compared to a chronic bronchitis (formerly GOLD stage 0) cohort. 
Although their observed reduction did not reach statistical significance the comparison 
was not made with a healthy control group as in our current study. There have been very 
few other studies investigating physical activity in mild to moderate COPD patients.  A 
multi-centre study recently found a reduction in activity in early disease from stage II 
COPD onwards compared to healthy controls, however this study had only a small number 
of patients (n=9) with GOLD stage I disease (Troosters 2010a). There is evidence to suggest 
that symptomatic GOLD stage I patients experience dynamic hyperinflation associated 
with dyspnoea during exercise compared to control subjects (Ofir 2008). GOLD stage I 
patients in our study had a significantly higher MRC dyspnoea score compared to healthy 
controls and this may therefore provide a mechanism for the initial reduction in physical 
activity seen early in the disease process. 
 
The reduction in physical activity in stage I COPD and its association with USRFCSA allows 
discussion of a potential mechanism for reduced quadriceps bulk in mild disease. Stage II-
IV patients also demonstrated a reduction in quadriceps bulk compared to control subjects 
but this was not significantly different from the stage I group suggesting that a threshold 
level of physical inactivity, reached early in the disease process, triggers the depletion in 
muscle bulk. There is evidence from the Copenhagen City Heart Study (Garcia-Aymerich 
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2007) and elsewhere (Hopkinson 2010) that physical inactivity may in fact precede the 
occurrence of airflow obstruction and that it is a significant aetiological factor for the 
development of COPD. In addition, recent data has highlighted physical activity to be a 
strong predictor of all-cause mortality in COPD (Waschki 2011) emphasising its importance 
in this patient group, although that study compared activity to measures of whole body 
FFM and BMI, rather than quadriceps muscle bulk or strength.  In keeping with previous 
work (Garcia-Rio 2009; Watz 2009), we found that lung function is associated with the 
level of physical activity in COPD, with RV/TLC ratio rather than FEV1% predicted found to 
be an independent predictor of physical activity level in stage II-IV disease. USRFCSA was 
also independently associated with RV/TLC ratio and IC, but not FEV1% predicted, 
highlighting that although FEV1 can be used for classifying the severity of airflow 
obstruction (Pellegrino 2005) it does not reflect the true severity of the disease. There is 
increasing evidence to support measures of gas trapping and thoracic distension as better 
indicators of disease severity than airflow obstruction in COPD (Hannink 2010; O'Donnell 
2012). Our finding that USRFCSA has a stronger association with physical activity in the mild 
compared to more advanced group, suggests that these pulmonary factors are more 
limiting to activity in moderate-severe patients, compared to those with mild COPD where 
the association between muscle wasting and inactivity is more pronounced.  
 
Importantly, in our study whole-body measurement of FFMI was similar in controls and 
patients with mild disease, although USRFCSA was reduced, supporting local disuse as a key 
factor. Disuse may also increase susceptibility to systemic factors, particularly the effects 
of smoking which is in itself known to be associated with skeletal muscle oxidative stress 
(Montes de Oca 2008) and quadriceps weakness (van den Borst 2011). It should be noted 
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however that inactivity may act as a significant confounder when observing quadriceps 
dysfunction as an effect of smoking. Further studies are needed to explore whether the 
fibre type switch from oxidative type I fibres to anaerobic type II fibres reported in 
advanced COPD (Gosker 2007), occurs earlier in the disease process as a consequence of 
physical inactivity interacting with systemic effects.  
 
Of note from this study, quadriceps strength and USRFCSA were shown to be associated 
with health status in COPD patients, measured using the COPD assessment test (CAT). This 
finding highlights the importance of these outcome measures as markers of quality of life 
in this patient population and indicates their likely influence on activities of daily living. A 
recent multicentre trial has identified an improvement in CAT score with pulmonary 
rehabilitation (Dodd 2011) and the association with quadriceps dysfunction may well 
relate to this positive finding. 
 
In addition, the bioelectrical impedance ratio (Z200/Z5) was found to show strong 
associations with USRFCSA and quadriceps strength in COPD patients. As previously 
described, this ratio is thought to give an index of separation of the extracellular and total 
body water compartments. In contrast to the use of bioelectrical impedance analysis to 
calculate fat free mass using regression equations which may include height, weight and 
gender, the impedance ratio is based on direct measurements. Interestingly, a higher ratio 
has been associated with greater disease severity in patients with heart failure (Castillo 
Martinez 2007). The impedance ratio therefore warrants further investigation as a non-
invasive biomarker in COPD.  
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3.4.3 Critique of the method 
 
  
Although this study cannot establish causation, the association between physical inactivity 
and depletion in muscle bulk in mild disease is strongly suggestive of a mechanistic link. 
The patients recruited in this cross-sectional study are a combination of those seen in 
hospital outpatients as well as those from the community setting who are not seen in 
secondary care (table 3.1). Importantly, the patients with mild disease had very similar 
physical activity levels to another published GOLD stage I cohort (Watz 2009), suggesting 
that our group is representative of the general COPD population.  
 
The strong correlation of ultrasound RFCSA with both mid-thigh and rectus femoris CT 
measurements supports the use of rectus femoris as a representation of quadriceps bulk 
and confirms our initial findings in a small cohort of COPD patients (Seymour 2009). 
Furthermore, inter-observer and inter-occasion agreement for USRFCSA measurement in 
this study were similar to that for other muscle ultrasound imaging (O'Sullivan 2007). The 
key areas for measurement error in our experience result from operator accuracy of probe 
position in relation to surface anatomy and inaccurate cursor outline of the acquired 
rectus femoris image, both of which may be related to operator training and experience. 
CT and MR imaging modalities have been shown to have an advantage over ultrasound in 
serial measurements which is likely to relate to use of bony landmarks for measurement 
position in comparison to the use of surface anatomy. However, a randomised controlled 
trial using electrical muscle stimulation to reduce muscle wasting in the intensive care unit 
(ICU) setting has shown that ultrasound measurement of the quadriceps can be used as a 
bedside imaging modality for identifying changes in muscle bulk following intervention 
(Gerovasili 2009). In addition, a more recent pilot study in COPD patients has found that 
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serial ultrasound measurements of the quadriceps can also detect changes in muscle mass 
in response to resistance training (Menon 2012).  
 
In relation to the objective measurements of activity in this study, both daily step count 
and PAL were used as measures of daily physical activity, although the Sensewear 
armband monitor has been shown to underestimate step count at slow walking speeds 
(Hill 2010). This may account for differences in the statistical strength of these activity 
variables when incorporated into the regression analyses. Importantly, the study 
participants showed good compliance with the Sensewear armband in keeping with recent 
data on the wearing time of this device in COPD and healthy subjects (Waschki 2012). 
 
 
 
3.4.4 Conclusion 
 
 
In summary, this study has shown that quadriceps wasting identified by USRFCSA exists in 
patients with mild, as well as advanced, COPD. Quadriceps bulk was associated with daily 
physical activity, independent of airflow limitation, in GOLD stage I disease. Our data 
suggest that, rather than being an end-stage phenomenon, quadriceps wasting occurs in a 
substantial minority of COPD patients including those with early disease. Ultrasound 
measurement of rectus femoris cross-sectional area has potential as a physiological 
biomarker in COPD and the identification of these patients may guide early lifestyle and 
therapeutic interventions. 
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Chapter 4: Randomised Controlled 
Trial of Effects of ACE-inhibition on 
Skeletal Muscle Dysfunction in COPD 
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4.1 Introduction 
 
 
4.1.1 Background  
 
 
Skeletal muscle impairment is a key complication of chronic obstructive pulmonary disease 
(COPD), affecting approximately a third of patients independent of the degree of airflow 
obstruction (Seymour 2010b). Quadriceps weakness in COPD has been associated with 
reduced exercise capacity (Gosselink 1996), impaired health status (Shrikrishna 2012a), 
and mortality in patients with moderate to severe disease (Swallow 2007a). Importantly 
pulmonary rehabilitation, which improves exercise performance and reduces healthcare 
utilisation, also increases quadriceps strength (Troosters 2000; Seymour 2010a).  
 
 
4.1.2 Rationale and hypothesis  
 
 
The mechanisms responsible for skeletal muscle dysfunction in COPD are likely to be 
multifactorial, however there are compelling data to suggest that chronic activation of the 
renin angiotensin system (RAS) may represent a key pathophysiological pathway 
(Shrikrishna 2012b). Although best known for its role in salt/water homeostasis, the RAS 
occurs in many tissues, including skeletal muscle (Schaufelberger 1998), regulating a 
diverse range of local inflammatory and metabolic processes (Carter 2005). Angiotensin-
converting enzyme (ACE) is a key RAS component catalysing the synthesis of angiotensin II 
and the breakdown of vasoactive kinins (Hanif 2010). Data supporting an influence of ACE 
on muscle phenotype come from the impact of genetic polymorphisms (Williams 2000; 
Hopkinson 2004b; Hopkinson 2006), epidemiological data from patient cohorts on ACE-
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inhibitors (Onder 2002; Di Bari 2004; Maggio 2006) and from interventional studies 
(Andreas 2006; Sumukadas 2007; Di Marco 2010).   
 
Endogenous variation in ACE levels as a result of polymorphism of the ACE gene influences 
the endurance versus strength muscle phenotype in COPD, with the presence of the 
deletion allele (D) associated with greater quadriceps strength in COPD (Hopkinson 
2004b). In addition, a polymorphism determining a reduction in bradykinin receptor 
expression has been associated with a reduced fat free mass and quadriceps strength in 
COPD patients (Hopkinson 2006).  Epidemiological evidence for a role of the renin-
angiotensin system in muscle wasting comes from observations in hypertensive cohorts in 
which treatment with ACE-inhibition has been associated with increased locomotor muscle 
size (Di Bari 2004) and strength (Onder 2002). Furthermore, previous randomised 
controlled trials have reported clinical benefits of ACE inhibition; a trial in elderly people 
with limited mobility found that the ACE inhibitor, perindopril, increased six minute 
walking distance (Sumukadas 2007). In COPD patients, a pilot study found enalapril to 
increase peak work rate (Di Marco 2010) while in a randomised controlled trial of an 
angiotensin II receptor blocker,  a numerical increase in quadriceps strength was found in 
the treatment group although, not being powered for this end-point, this difference failed 
to achieve statistical significance (Andreas 2006). 
  
Given this strong evidence base, we hypothesised that ACE-inhibition would have a 
beneficial effect on skeletal muscle dysfunction in COPD patients.  To strengthen the 
design of the trial we used a stratified medicine approach, selecting patients with 
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quadriceps weakness and using primary endpoints consistent with the proposed mode of 
action. 
 
 
4.2 Methods 
 
 
4.2.1 Trial design  
 
 
The study was a double-blind, randomised, placebo-controlled, parallel-group trial.  
Patients were randomly allocated to either ACE-inhibitor (fosinopril 10-20mg) or placebo 
(lactose). A pharmacy controlled 1:1 randomisation in blocks of 4 using consecutive 
numbers was performed, by the Clinical Trials Department, Royal Free Hampstead NHS 
Trust, UK. The trial was registered prospectively on a publically accessible database 
(www.controlled-trials.com/ISRCTN05581879). 
 
 
4.2.2 Inclusion and exclusion criteria 
 
 
Study inclusion criteria were patients diagnosed with COPD based on NICE and GOLD 
criteria and the presence of quadriceps weakness defined as a quadriceps maximum 
voluntary contraction (QMVC) in kilograms less than 120% of the patient’s body mass 
index (Swallow 2007a). Exclusion criteria were patients within three months of pulmonary 
rehabilitation or within one month of an exacerbation, and those with a co-morbidity 
including cardiac failure, diabetes, renal disease or rheumatoid arthritis. Patients on ACE-
inhibitors, angiotensin II receptor blockers or warfarin were also excluded. 
 
121 
 
 
4.2.3 Trial protocol 
 
 
Visit 1 Screening (day -7) - Informed consent was obtained and at this initial screening visit 
patients had a baseline assessment including – 
 Review of medical history and measurements of BMI, resting blood pressure and fat 
free mass index 
 MRC dyspnoea score, St George’s Respiratory Questionnaire and CAT score 
 Spirometry, gas transfer, lung volumes by body plethysmography and arterial 
blood gases 
 Incremental Shuttle Walk test 
 Quadriceps maximal voluntary contraction and quadriceps twitch force 
 Quadriceps endurance assessed using repetitive magnetic stimulation 
 Mid-thigh cross-sectional area measured by CT 
 Blood drawn for renal function, inflammatory markers, serum ACE and ACE 
genotype. 
 Quadriceps muscle biopsy  
 Physical activity recorded for 1 week at baseline using a multisensory armband 
accelerometer 
 
Visit 2 (day 0) Treatment start – Patients were randomised to either fosinopril 10mg once a 
day (encapsulated tablets) or matched placebo starting the first dose that evening. Written 
information was given concerning potential side effects. 
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Phone call (day 1) – Patients were contacted the day after starting the study medication to 
ensure they had not experienced side effects. 
 
Visit 3 (Day 7) Treatment escalation – Resting blood pressure and renal function were 
reviewed by an independent assessor and if satisfactory the dose was increased to two 
capsules once per day of either placebo or fosinopril 10mg (i.e maximum dose 20mg). Dose 
was not escalated if systolic BP<110mmHg. QMVC was re-measured and blood drawn for 
renal function. If there was an increase in creatinine of >30%, the patient was withdrawn 
from the study and referred for renal investigation. 
 
Phone Call (Day 9) – patients were contacted to ensure that they had tolerated the dose 
change. If not they were told to go back down to one capsule per day. 
 
Phone Call (Day 28) – patients were contacted for compliance and to report any problems. 
 
Phone Call (Day 49) – patients were contacted for compliance and to report any problems. 
 
Visit 4 Follow up visit (Day 90) – Baseline measurements (excluding activity monitoring) 
were repeated – a summary of the trial schedule is outlined in table 4.1.  
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Table 4.1: Protocol for randomised controlled trial of effects of ACE-inhibition on muscle 
weakness in COPD  
 
 
 
Day           
7 
Screening 
Day           
0 
Treatment 
start 
Day       
1 
Day           
7 
Dose 
titration  
Day  
9 
Day 
28 
Day 
49 
Day 
90 
End 
visit 
History X   X    X 
Quadriceps 
function - 
Endurance 
and QMVC 
X   X    X 
FFMI X       X 
Bloods for 
genotype & 
inflammatory 
markers 
X   X    X 
U&E’s to 
assess renal 
function/FBC 
X   X    X 
SGRQ/CAT X       X 
PFT’s X       X 
Mid-thigh CT X       X 
ISWT X       X 
Quadriceps 
biopsy X       X 
Phone call   X X X X X  
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4.2.4 Primary and secondary physiological outcome measures 
 
 
(1) Effect of ACE-I on quadriceps endurance assessed non-volitionally (Primary) 
(2) Effect of ACE-I on quadriceps maximum voluntary contraction force 
(3) Effect of ACE-I on mid-thigh CT cross-sectional area 
 
 
4.2.5 Data analysis and statistics 
 
 
Pilot work using repetitive magnetic stimulation in COPD patients identified the time taken 
to fatigue to a force of 50% of baseline (endurance half-time) as a mean(SD) of 80 (30) 
seconds. To detect a 20 seconds (25%) increase in time to fatigue using non-volitional 
quadriceps endurance in the fosinopril versus placebo groups, with an 80% power at the 
5% significance level, would require 54 patients randomised on a 1:1 basis.  To allow for a 
30% drop out rate, 80 patients were targeted for recruitment. Data are presented as mean 
± standard deviation, with accompanying p value, and were analysed using paired or 
independent t-tests. Analysis was performed using StatView 5.0 (Abacus concepts, Inc., 
Berkeley, CA, USA) with p<0.05 considered statistically significant. Figure construction was 
performed using GraphPad Prism Version 5.0 (GraphPad Software, San Diego, California, 
USA). 
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4.3 Results 
 
 
One hundred and seventeen patients were screened for study participation and 80 
patients underwent randomisation. There were 8 withdrawals from the treatment group 
and 5 from the placebo group. Further details are shown in the CONSORT diagram (figure 
4.1).  
 
 
4.3.1 Consort diagram  
 
 
 
Figure 4.1: Consort recruitment diagram for enrolment and follow up.  
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4.3.2 Baseline characteristics of placebo and treatment groups 
 
 
The placebo and treatment groups were well matched for age, gender, and lung function 
parameters (table 4.2) and there were no statistically significant baseline differences in 
body composition and quadriceps muscle function (table 4.3).  
 
Table 4.2: Baseline characteristics of placebo and treatment groups 
 
 
Placebo group 
(n=41) 
mean (SD) 
Treatment group 
(n=39) 
mean (SD) 
p 
value 
Age (years) 64.6 (7.3) 66.3 (8.2) 0.33 
Gender (M/F) 23/18 19/20 0.51 
BMI (kg/m2) 24.3 (4.0) 25.0 (5.8) 0.51 
FFMI (kg/m2) 17.0 (2.1) 17.3 (2.6) 0.60 
Smoking (pack years) 53.3 (25.1) 49.8 (33.1) 0.59 
Current smokers (%) 24 28 0.70 
Outpatients (%) 66 67 0.94 
Long-acting beta agonist (%) 93 82 0.15 
Long-acting anticholinergic (%) 88 87 0.93 
Inhaled corticosteroid (%) 90 82 0.15 
Oral corticosteroid (% ≥5mg/day) 2 5 0.53 
FEV1% predicted 40.1 (20.6) 45.8 (20.5) 0.22 
TLco% predicted 41.8 (20.9) 44.0 (19.2) 0.64 
RV%TLC ratio 58.2 (9.9) 55.8 (10.7) 0.29 
PaO2 (kPa) 9.7 (1.4) 9.6 (1.4) 0.82 
PaCO2 (kPa) 5.2 (0.6) 5.1 (0.4) 0.18 
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Placebo group 
(n=41) 
mean (SD) 
Treatment group 
(n=39) 
mean (SD) 
p 
value 
SGRQ (Symptoms) 56.5 (23.7) 49.6 (21.3) 0.17 
SGRQ (Activity) 70.8 (25.8) 71.1 (17.2) 0.96 
SGRQ (Impacts) 40.8 (22.8) 31.3 (16.2) 0.04 
SGRQ (Total) 52.5 (22.0) 46.4 (14.9) 0.15 
CAT score 22.8 (8.5) 20.8 (8.1) 0.34 
Daily step count 4499 (3462) 4504 (3109) 0.99 
Physical activity level (PAL) 1.4 (0.18) 1.4 (0.16) 0.66 
Systolic BP (mmHg) 134 (15) 138 (19) 0.35 
Diastolic BP (mmHg) 85 (10) 85 (11) 0.84 
Beta-blocker (%) 2 0 0.33 
Calcium channel blocker (%) 7 10 0.65 
Diuretic (%) 0 2 0.31 
Serum NT-pro BNP (pg/ml) 109.0 (99.8) 105.0 (64.0) 0.85 
ACE genotype (DD,ID,II) % 39,44,17 38,46,16 0.94 
 
Abbreviations: BMI - body mass index; FFMI – fat free mass index; FEV1 - forced expiratory 
volume in 1 second; TLco – carbon monoxide diffusing capacity; RV – residual volume; TLC – 
total lung capacity; SGRQ – St George’s respiratory questionnaire; CAT – COPD assessment 
test; BP – blood pressure; NT-proBNP – N-terminal pro-B-type natriuretic peptide; ACE – 
angiotensin-converting enzyme; Outpatients – defined as any previous hospital clinic 
attendance. 
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Table 4.3: Baseline quadriceps and exercise measurements in placebo and treatment groups 
 
 
Placebo group 
mean (SD) 
Treatment group 
mean (SD) 
p 
value 
QMVC (kg) 24.9 (4.9) 25.0 (7.4) 0.98 
TwQ (kg) 10.7 (3.0) 9.7 (3.4) 0.21 
MTCSA (cm
2) 93.3 (22.4) 93.0 (26.1) 0.96 
Endurance half-time (s) 61.2 (35.5) 70.6 (31.9) 0.30 
ISWT (m) 247 (132) 242 (128) 0.87 
 
Abbreviations: QMVC – quadriceps maximum voluntary contraction; TwQ – quadriceps twitch 
force; MTCSA – mid-thigh cross-sectional area; ISWT – incremental shuttle walk test.  
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4.3.3 Effect of ACE-inhibition on quadriceps endurance and exercise capacity 
 
 
At 3 months, there was no significant difference in quadriceps endurance half-time 
assessed non-volitionally by repetitive magnetic stimulation (fosinopril ∆+5.1s, 95%CI -4.3 
to 14.5, p=0.27 vs. placebo ∆+4.6s, 95%CI -5.8 to 15.1, p=0.37; between group difference 
0.5s 95%CI -13.3 to 14.3, p=0.94) (figure 4.2). There was also no significant change in 
incremental shuttle walk distance at 3 months in the two groups (fosinopril ∆+7.1m, 95%CI 
-5.5 to 19.7, p=0.26 vs. placebo ∆+17.1m, 95%CI -10.6 to 44.8, p=0.22; between group 
difference -10m 95%CI -39.8 to 19.8, p=0.51) (figure 4.3).   
 
 
 
Figure 4.2: Quadriceps endurance following 3 months ACE-inhibition vs. placebo              
(Data shown as mean with cross bars representing the standard error of the mean - SEM, 
between group p=0.94; not significant - NS).  
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Figure 4.3: Incremental shuttle walk distance following 3 months of ACE-inhibition vs. 
placebo (Placebo group – top; Treatment group – bottom). 
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4.3.4 Effect of ACE-inhibition on quadriceps strength and cross-sectional area 
 
 
Quadriceps maximal voluntary contraction improved in both groups (fosinopril ∆+1.1kg, 
95%CI 0.03-2.2, p=0.045 vs. placebo ∆+3.6kg, 95%CI 2.1-5.0, p<0.0001) with a greater 
increase in the placebo arm (between group difference 2.5kg, 95%CI 0.7 to 4.3, p=0.009) 
(figure 4.4). There was also a trend towards an increase in quadriceps twitch force in the 
placebo versus treatment group (fosinopril ∆-0.28kg, 95%CI -1.0 to 0.45, p=0.43 vs. 
placebo ∆+0.57kg, 95%CI 0.01 to 1.1, p=0.046; between group difference -0.85kg 95%CI -
1.7 to 0.03, p=0.06) (figure 4.5). Mid-thigh cross-sectional area showed no significant 
differences at 3 months, but trended to an increase in the placebo group (fosinopril ∆-
0.60cm2, 95%CI -2.1 to 0.91, p=0.42 vs. placebo ∆+1.0cm2, 95%CI -0.21 to 2.2, p=0.10; 
between group difference -1.6cm2 95%CI -3.5 to 0.27, p=0.09) (figure 4.6).   
 
 
Figure 4.4: Quadriceps strength after 3 months ACE-inhibition vs. placebo   
(Data shown as mean with cross bars representing SEM; not significant - NS). 
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Figure 4.5: Quadriceps twitch force following 3 months ACE-inhibition vs. placebo  
(Data shown as mean with cross bars representing SEM; not significant - NS). 
 
Figure 4.6: Quadriceps MTCSA following 3 months ACE-inhibition vs. placebo 
(Data shown as mean with cross bars representing SEM; not significant - NS). 
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4.3.5 Effect of ACE-inhibition on blood pressure, lung function and health status 
 
 
A significant reduction was demonstrated in systolic blood pressure in the treatment arm 
compared to placebo (fosinopril ∆-12.7mmHg, 95%CI -20.3 to -5.1, p=0.002 vs. placebo ∆-
2.2mmHg, 95%CI -8.1 to 3.7, p=0.46; between group difference -10.5mmHg, 95%CI -19.9 
to -1.1, p=0.03) (figure 4.7). Diastolic blood pressure was also reduced in the treatment 
group (fosinopril ∆-7.0mmHg, 95%CI -11.5 to -2.4, p=0.004 vs. placebo ∆-1.2mmHg, 95%CI 
-5.2 to 2.9, p=0.56; between group difference -5.8mmHg, 95%CI -11.7 to 0.11, p=0.05) 
(figure 4.8). Lung function parameters including FEV1% predicted, DLco% predicted, 
RV/TLC ratio and arterial blood gases showed no significant change between groups at 3 
months. Health-related quality of life measures which included SGRQ and CAT score, also 
did not vary significantly between groups (see table 4.4). 
 
 
 
Figure 4.7: Systolic blood pressure following 3 months ACE-inhibition vs. placebo  
(Data shown as mean with cross bars representing SEM; not significant - NS). 
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Figure 4.8: Diastolic blood pressure following 3 months ACE-inhibition vs. placebo  
(Data shown as mean with cross bars representing SEM; not significant - NS). 
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Table 4.4: Change in physiological and HRQOL outcomes following 3 months of ACE-
inhibition 
 
 
Placebo group 
mean (SD) 
Treatment group 
mean (SD) 
p 
value 
Endurance half-time (s) 4.6 (28.0) 5.1 (24.2) 0.94 
QMVC (kg) 3.6 (4.3) 1.1 (2.9) 0.009 
TwQ (kg) 0.6 (1.5) -0.3 (1.8) 0.06 
MTCSA (cm
2) 1.0 (3.7) -0.6 (4.1) 0.09 
ISWT (m) 17.1 (75.6) 7.1 (34.5) 0.51 
Systolic BP (mmHg) -2.2 (16.4) -12.7 (20.8) 0.03 
Diastolic BP (mmHg) -1.2 (11.1) -7.0 (12.4) 0.05 
FEV1% pred 2.7 (5.6) 1.7 (6.8) 0.50 
TLco% pred 1.2 (4.7) -0.23 (4.3) 0.20 
RV%TLC ratio -3.7 (14.0) -1.2 (4.3) 0.35 
PaO2 (kPa) -0.12 (0.8) -0.05 (1.1) 0.77 
PaCO2 (kPa) -0.02 (0.5) -0.05 (0.4) 0.79 
SGRQ (Symptoms) -1.8 (19.4) 4.0 (21.0) 0.25 
SGRQ (Activity) -1.5 (9.9) -1.5 (11.9) 0.99 
SGRQ (Impacts) -0.7 (12.2) 2.3 (9.4) 0.28 
SGRQ (Total) -1.1 (10.1) 1.5 (7.9) 0.25 
CAT score -2.6 (5.7) -0.3 (6.2) 0.18 
 
Abbreviations: QMVC – quadriceps maximum voluntary contraction; TwQ – quadriceps twitch 
force; MTCSA – mid-thigh cross-sectional area; ISWT – incremental shuttle walk test; BP – blood 
pressure; FEV1 - forced expiratory volume in 1 second; TLco – carbon monoxide diffusing 
capacity; RV – residual volume; TLC – total lung capacity; PaO2 / CO2 - arterial partial pressure 
of oxygen / carbon dioxide; SGRQ – St George’s respiratory questionnaire; CAT – COPD 
assessment test. 
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4.3.6 Influence of ACE/Bradykinin polymorphisms  
 
 
Patients were also stratified by ACE and bradykinin genotype (table 4.5 and table 4.6). 
Across ACE genotype, the patients were well matched except for a lower FEV1% predicted 
in those homozygous for the insertion (I) allele. There were no significant baseline 
differences across bradykinin receptor genotype. 
 
Table 4.5: Baseline physiological data when stratified by ACE genotype  
 
   
DD (n=31) 
Mean (SD) 
 
ID (n=36) 
Mean (SD) 
 
II (n=13) 
Mean (SD) 
 
p value 
     
Age  66.4 (8.3) 64.8 (7.7) 65 (6.9) 0.69 
Gender 15/16   19/17 8/5   0.74  
BMI (kg/m2) 24.6 (5)   24.9 (5.2) 23.8 (4.6)   0.80  
FFMI (kg/m2) 17.4 (2.6)   17.2 (2.3) 16.6 (2)   0.63  
FEV1% pred 48.9 (18.8)   42.7 (22.7)   29.3 (10.6)   0.01 
QMVC (kg) 25.7 (6.3)   25 (6.1)   23.2 (6.7)   0.49   
USRFCSA (mm
2) 498 (127) 522 (123)   487 (133) 0.62 
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Table 4.6: Baseline physiological data when stratified by bradykinin receptor polymorphism 
 
 
   
+9/+9 (n=27) 
Mean (SD) 
 
+9/-9 (n=35) 
Mean (SD) 
 
-9/-9 (n=18) 
Mean (SD) 
 
p  
value 
     
Age  67.2 (7.2) 64.7 (7.3) 64.2 (9.3) 0.33 
Gender 12/15   21/14 9/9   0.47  
BMI (kg/m2) 23.9 (5.1)   25.4 (5.1) 24.3 (4.5)   0.46  
FFMI (kg/m2) 16.8 (2.5)   17.5 (2.3) 17 (2.3)    0.48 
FEV1% pred 42.4 (21.8)   45.2 (22.1)   39.1 (15.5)   0.60 
QMVC (kg) 23.5 (6.1)   26.2 (6.1)   24.6 (6.4)   0.20   
USRFCSA (mm
2) 482 (121) 530 (136)   501 (112) 0.30 
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The response to ACE-inhibition vs. placebo was also assessed by ACE and bradykinin 
receptor genotype as shown in table 4.7. When divided by ACE genotype, patients 
homozygous for the insertion allele (II) showed an increase in ISWT following treatment 
(fosinopril ∆+37.5m vs. placebo ∆-20m) compared to those homozygous for the D allele 
who showed a reduced effect with treatment (fosinopril ∆+3m vs. placebo ∆+56m) 
(ANOVA p=0.02). Twitch force also increased in patients with the II genotype following 
treatment (fosinopril ∆+2.01kg vs. placebo ∆-0.03kg) when compared to other genotypes; 
DD genotype (fosinopril ∆-0.44kg vs. placebo ∆+0.68kg), ID genotype (fosinopril ∆-0.67kg 
vs. placebo ∆+0.80kg) (ANOVA p=0.02). In a separate analysis for treatment response by 
presence of an I allele (ID and II vs. DD), using ANOVA, ISWT remained significant (p=0.01), 
but no significant difference was found for twitch force (p=0.67). 
 
When analysing bradykinin receptor genotypes, only TLco% predicted showed a difference 
in treatment response (-9/-9 genotype; fosinopril ∆+1% pred vs. placebo ∆-0.5% pred) vs 
(+9/-9 genotype; fosinopril ∆-2% pred vs. placebo ∆+3% pred) vs (+9/+9 genotype; 
fosinopril ∆+1.6% pred vs. placebo ∆+0.4% pred) (ANOVA p=0.03). In a separate analysis 
for TLco% predicted treatment response by presence vs. absence of the -9 allele, (-9/-9 
and +9/-9 vs. +9/+9) no significant difference was found (p=0.11). 
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Table 4.7: Change in physiological and HRQOL outcomes following 3 months ACE-inhibition 
when stratified by ACE and bradykinin genotypes. 
 
 
 
Change in treatment vs. 
placebo 
stratified by ACE genotype  
(DD vs. ID vs. II) 
p value (ANOVA) 
Change in treatment vs. placebo 
 stratified by bradykinin 
polymorphism 
(+9/+9, -9/+9, -9/-9) 
p value (ANOVA) 
Endurance half-time (s) 0.68 0.50 
QMVC (kg) 0.62 0.79 
TwQ (kg) 0.02  0.86 
MTCSA (cm
2) 0.43 0.97 
ISWT (m) 0.02 0.40 
Systolic BP (mmHg) 0.96 0.53 
Diastolic BP (mmHg) 0.20 0.12 
FEV1% pred 0.11 0.67 
TLco% pred 0.31 0.03 
RV%TLC ratio 0.23 0.32 
PaO2 (kPa) 0.54 0.44 
PaCO2 (kPa) 0.64 0.91 
SGRQ (Symptoms) 0.12 0.20 
SGRQ (Activity) 0.36 0.20 
SGRQ (Impacts) 0.23 0.82 
SGRQ (Total) 0.09 0.31 
CAT score 0.68  0.30 
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4.4 Discussion 
 
 
4.4.1 Summary of results 
 
 
Fosinopril did not have a beneficial effect on quadriceps muscle function in moderate to 
severe COPD patients selected for quadriceps weakness, although blood pressure 
measurements confirmed adherence and biological activity of the drug.  The present data 
do not support the use of ACE inhibitors to augment muscle phenotype in patients with 
COPD.    
 
 
4.4.2 Significance of the findings 
 
 
These findings are unexpected given previous data supporting a beneficial effect of ACE- 
inhibition on skeletal muscle function, and reinforce the importance of conducting 
prospective blinded trials. An observational study assessed the relationship between ACE- 
inhibitor use and muscle strength in 641 elderly hypertensive women participating in the 
Women’s Health and Aging Study (Onder 2002). They found that at 3 years’ follow up, 
participants taking an ACE-inhibitor continuously had a lower mean decline in both knee 
extensor muscle strength and walking speed than those using other antihypertensives and 
those not on antihypertensive medications. In addition, cross-sectional data from 2,431 
hypertensive subjects participating in the Health, Aging and Body Composition (Health 
ABC) study was used to evaluate whether ACE-inhibitor treatment was associated with a 
larger lower extremity muscle mass compared to the use of other antihypertensive 
medications (Di Bari 2004), and found that lower extremity muscle mass (assessed by 
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DEXA) was larger in the ACE-inhibitor group.  They also showed that duration of exposure 
to ACE-inhibitors was associated with greater muscle mass.  
 
Interventional studies of ACE-inhibition have also suggested a treatment effect. A 
randomised controlled trial in an elderly population (n=95, mean age 77 years) with self-
reported difficulties in mobility, showed that 5 months of perindopril treatment 
significantly improved 6 minute walk distance (31.4m, 95% CI 10.8-51.9m, p=0.003) 
compared to placebo (Sumukadas 2007). Health-related quality of life deteriorated in the 
placebo group but was maintained in the perindopril group. Interestingly this cohort 
included current and ex-smokers and the improvement was observed in the absence of 
heart failure in the participants.  
 
A small double blind, placebo controlled study has evaluated the effects of 4 weeks 
treatment with enalapril on exercise performance in 21 COPD patients with no evidence of 
cardiovascular co-morbidities (Di Marco 2010). Enalapril did not have an effect on the 
ventilatory response to exercise (VE/VCO2 slope) or on peak O2 consumption. However, 
enalapril did significantly improve O2 pulse and peak work rate compared to placebo. ACE 
genotype did not significantly affect patient response to treatment. The improved 
cardiovascular response to exercise may be attributable to a combination of greater 
cardiac efficiency, a reduced pulmonary arterial pressure and reduced neurohumoral 
activation influencing systemic effects on skeletal muscle function.  
 
142 
 
 
There are a number of possible factors that may explain why fosinopril was not effective in 
the present study given previous data. These are discussed below and include the patient 
population studied, the choice of ACE-inhibitor, the treatment duration and the influence 
of physical inactivity. A further possibility is that ACE-inhibitors in fact create a more 
“benign” intramuscular environment effectively removing a training stimulus. 
 
 
Patient selection 
 
 
We adopted a stratified medicine approach, based on a quadriceps weakness patient 
phenotype, so as to focus on those COPD patients with a level of skeletal muscle 
dysfunction known to be associated with worse survival (Swallow 2007a). It may however, 
be the case that at this stage the weakest patients have a limited ability to respond to 
treatment and the low physical activity level found at baseline may reflect this. The level of 
inactivity could explain the discrepancy between the present data and the effect of ACE-
inhibitors in relatively healthy populations being treated for hypertension (Onder 2002). 
There is also evidence that an exercise stimulus may be needed for ACE-inhibition to 
promote adaptive changes in skeletal muscle including an increase in capillary density 
(Guo 2010) and enhancement of insulin-stimulated muscle glucose transport (Steen 1999). 
Therefore the current data do not preclude the possibility that the use of ACE-inhibition in 
the context of pulmonary rehabilitation may yield benefit. 
 
This trial was not prospectively stratified and powered on ACE genotype, and therefore the 
value of the post-hoc analysis of a genotype specific response is limited. Although patients 
homozygous for the insertion allele (II) did show an improved treatment response for 
ISWT and twitch force with treatment compared to the DD group, the numbers of II 
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subjects was very small and therefore requires investigation in a larger cohort. 
Interestingly a previous study did show a trend towards an increase in the treatment effect 
of ACE-inhibition on O2 pulse in COPD patients homozygous for the II allele (Di Marco 
2010). As this ACE genotype is associated with increased endurance in normal populations, 
this potential enhanced treatment response in COPD does warrant further evaluation.  
In addition, the difference observed in this trial in transfer factor treatment response with 
bradykinin receptor genotype although small and not maintained when analysed by 
presence of a single allele, again highlights the need for specific studies in this area.  
 
 
Choice of ACE-inhibitor 
 
 
The beneficial effects seen with perindopril and enalapril in previous studies (Sumukadas 
2007; Di Marco 2010) highlight that type of ACE-inhibitor used may influence outcome. 
Fosinopril was chosen as the ACE-inhibitor for this study due to its high lipophilicity and its 
hepatic as well as renal elimination. However, although a class effect is seen for ACE-
inhibitors in the context of hypertension, any potential anti-inflammatory and muscle-
specific effects may be specific to individual compounds with differing phosphinyl or 
carboxyl containing groups; enalapril, perindopril, ramipril and lisinopril all contain a 
carboxyl group, whereas fosinopril contains a phosphinyl group. Interestingly, a recent 
randomised placebo controlled trial of ACE-inhibition and novel cardiovascular risk factors 
(TRAIN) study investigated the influence of fosinopril in 290 subjects (>55 years old) with a 
high cardiovascular disease risk profile and showed no effect on serum inflammatory 
biomarkers, haemostasis or endothelial function (Cesari 2009). A large substudy of 257 of 
the participants in this trial (mean age 66 years)  had a short physical battery score 
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assessment (encompassing 4 metre walking speed, balance and chair-stand tests) and 
measurement of handgrip strength at baseline and 6 months after the fosinopril/placebo 
intervention (Cesari 2010). This sub-study did not show a significant effect on strength or 
physical performance. This finding may also relate to the heterogeneity of the group 
studied particularly in relation to co-morbidities such as cancer, stroke and diabetes.  
 
ACE-inhibition was chosen over ATII receptor blockade due to the additional effect on 
prevention of bradykinin degradation, however a randomised placebo controlled trial of 4 
months treatment with irbesartan in 60 COPD patients (Andreas 2006), did show a 10% 
increase in quadriceps strength in the treatment group. Although this result did not reach 
statistical significance, the study was not powered on locomotor muscle strength and 
patients were not stratified by ACE genotype.  
 
 
Effect of ACE-inhibition on intramuscular environment  
 
 
The improvements observed in quadriceps strength in the current trial warrant further 
discussion. The COPD subjects were included based on the presence of quadriceps 
weakness, and therefore it is not completely unexpected that a placebo effect was found 
in relation to volitional quadriceps strength over the 3 months study period. Indeed the 
existence of a placebo effect has been well documented in the context of functional 
exercise capacity in clinical trials of ACE-inhibition in heart failure (Olsson 2005) and in 
other studies of physical performance (Beedie 2009). However, the finding that this effect 
was greater in the placebo arm of the trial was unexpected.  While this could potentially 
be a chance effect it was accompanied by trends in the same direction for mid-thigh cross 
sectional area and quadriceps twitch force (both of which are independent of patient 
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effort). A possible reduction in skeletal muscle blood flow secondary to a reduced systemic 
blood pressure may explain the attenuated response observed with treatment. Evidence 
for this comes from animal models where captopril has been shown to increase maximal 
blood lactate during exercise and reduce exercise capacity in normotensive, sedentary rats 
(Minami 2004). A decrease in arteriole vasodilator function has also been identified in rat 
skeletal muscle following ACE-inhibition (Frisbee 1999) and in a chronic heart failure 
model, perindopril was not found to protect against alterations in skeletal muscle energy 
metabolism (Momken 2003).  
 
 
4.4.3 Critique of the method 
 
 
A strength of this study was that the quadriceps assessment was comprehensive including 
both volitional and non-volitional physiological outcomes. The study included COPD 
patients with quadriceps weakness defined as a quadriceps strength less than 120% of 
BMI. Although this cut-off was associated with greater mortality in moderate-severe COPD 
patients (Swallow 2007a), the possibility exists that the inclusion of COPD patients with 
varying degrees of skeletal muscle impairment may have enabled a wider assessment of 
potential responders.  
 
The influence of treatment on physical activity level was not assessed although the study 
did incorporate a baseline objective physical activity assessment, and confirmed a similar 
level of baseline activity in both groups. In addition, the incremental shuttle walk test was 
chosen as a field test for the trial, although patients performing this test may have been 
more limited by walking speed when compared to a self-paced six minute walk test. 
 
146 
 
 
 
Finally, the duration of this study was 3 months however the time needed for skeletal 
muscle adaptation following pharmacotherapy in these patients remains unclear, with 
ACE-inhibitor treatment duration ranging from 10 weeks to 12 months for studies of 
improved six minute walk distance in heart failure (Olsson 2005) and treatment for longer 
than 2 years in observational studies of hypertensive individuals (Di Bari 2004).  
 
 
4.4.4 Conclusion 
 
 
In summary, despite a strong theoretical basis for the study, this randomised controlled 
trial found that ACE-inhibition, in the form of fosinopril, did not improve quadriceps 
function in a COPD population with quadriceps weakness.  A placebo effect was observed 
on quadriceps strength which unexpectedly was greater than that observed in patients on 
an ACE-inhibitor. This study does not support a role for ACE-inhibitors alone in the 
treatment of skeletal muscle dysfunction in patients with COPD.  
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Chapter 5: Effects of ACE-inhibition on 
Skeletal Muscle Atrophy/Hypertrophy 
Signalling in COPD  
 
148 
 
 
5.1 Introduction  
 
 
5.1.1 Background 
 
 
The molecular mechanisms underlying the skeletal muscle dysfunction observed in COPD 
patients remain to be fully elucidated; however increasing evidence suggests a key role for 
the insulin-like growth factor-1 (IGF-1), produced in response to growth hormone, 
testosterone and mechanical stretch. IGF-1 acts through the PI3K/AKT pathway to 
inactivate FoxO transcription factors, thereby inhibiting expression of the atrogenes 
atrogin-1 and MuRF-1 to prevent muscle catabolism (Sandri 2006). IGF-1 also activates the 
mammalian target of rapamycin (mTOR) via PI3K/AKT signalling to promote muscle 
anabolism. It has been shown that IGF-1 levels are reduced in COPD patients in the stable 
state compared to healthy controls (Crul 2007).  Furthermore, in COPD patients 
undergoing pulmonary rehabilitation, increases in exercise capacity and fibre size are 
associated with upregulation of IGF-1 (Vogiatzis 2007; Vogiatzis 2010).    
 
 
5.1.2 Rationale and hypothesis 
 
 
Angiotensin II has relevance in the pathogenesis of muscle impairment in COPD, through 
modulation of the IGF-1 pathway as well as induction of pro-inflammatory cytokines and 
reactive oxygen species. The evidence for an influence of RAS comes from animal models 
(Song 2005; Cohn 2007; Yoshida 2010) where infusion of angiotensin II promotes muscle 
loss via an inhibitory effect on the IGF-1 system and stimulation of a catabolic pathway 
mediated by the ubiquitin ligases, MuRF-1 and atrogin-1 (Song 2005). These atrogenes 
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have been shown to be upregulated in the quadriceps of patients with COPD (Doucet 
2007), with ubiquitin-proteasome degradation thought to play a key role in the muscle 
atrophy observed (Debigare 2010; Doucet 2010). In addition, recent work by Rezk et al in a 
mouse model has shown an increase in IGF-1 expression seven days after angiotensin II 
induced diaphragm muscle atrophy, suggesting a potential involvement of IGF-1 in skeletal 
muscle regeneration following RAS related injury (Rezk 2012). Based on this evidence, we 
hypothesised that ACE-inhibition would have a beneficial effect on vastus lateralis 
atrogene expression in COPD patients with quadriceps weakness.  
 
 
 
5.2 Methods 
 
 
5.2.1 Participants and measurements 
 
 
Muscle biopsies were taken from the vastus lateralis at baseline and three months, as part 
of the double-blind randomised controlled trial described in chapter 4. Real-time 
quantitative PCR (RT-qPCR) was performed testing for atrophy/hypertrophy target genes 
and MHC isoforms (primer sequences shown in table 5.1) with normalisation to a 
reference housekeeping gene, RPLPO. Expression of phosphorylated 4EBP-1 was 
determined by enzyme-linked immunosorbent assay (ELISA). Blood samples were also 
taken at baseline and 3 months and analysed for inflammatory cytokines (IL-6, IL-8, IL-18 
and MCP-1), serum ACE activity, IGF-1, NT-pro-BNP, hs-CRP and fibrinogen, as previously 
described.  
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Table 5.1: Primer sequences 
 
 
 
 
 Forward sequence Reverse sequence  
RPLPO 
5’-TCTACAACCCTGA 
AGTGCTTGATATC-3’ 
5’-GCAGACAGAC 
ACTGGCAACAT-3’ 
 
Atrogin-1 
5’-GCAGCTGAACAA 
CATTCAGATCAC-3’ 
5’-CAGCCTCTGCA 
TGATGTTCAGT-3’ 
 
MuRF-1 
5’-CCTGAGAGCC 
ATTGACTTTGG-3’ 
5’-CTTCCCTTCTGT 
GGACTCTTCC-3’ 
 
IGF-1 
5’-CCACGATGC 
CTGTCTGAGG-3’ 
5’-TTTCAACAAG 
CCCACAGGGT-3’ 
 
MyoD 
5’-GACGGCATGA        
TGGACTACAG-3’ 
5’AGGCAGTCTA                     
G GCTCGACAC 
 
TGF-β 
5’-CCTGGCGAT                                  
ACCTCAGCAA 
5’-CCGGTGACATC                 
AAAGATAACCA-3’ 
 
MHC I 
5’CCCTGGAGACTT                       
TGTCTCATTAGG-3’ 
5’-AGCTGATGAC                 
CAACTTGCGC-3’ 
 
MHC IIA 
5’TCACTTATGACTT   
TTGTGTGAACCT-3’ 
5’CAATCTACCTAA  
ATTCCGCAAGC-3’ 
 
MHC IIX 
5’TGACCTGGGAC           
TCAGCAATG-3’ 
5’GGAGGAACAAT 
CCAACGTCAA-3’ 
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5.2.2 Primary and secondary molecular outcome measures 
 
 
(1) Effect of ACE-I on MuRF-1 and Atrogin-1 mRNA expression (Primary) 
 
(2) Effect of ACE-I on serum inflammatory markers and IGF-1 
 
 
5.2.3 Data and statistical analysis 
 
 
To detect a 70% decrease in MURF-1 mRNA expression in the fosinopril versus placebo 
groups, with an 80% power at the 5% significance level, would require 20 patients in each 
group (Doucet 2007).  Data are presented as mean ± standard deviation, with 
accompanying p value, and were analysed using paired or independent t-tests. Analysis 
was performed using StatView 5.0 (Abacus concepts, Inc., Berkeley, CA, USA) with p<0.05 
considered statistically significant. Figure construction was performed using GraphPad 
Prism Version 5.0 (GraphPad Software, San Diego, California, USA). 
 
 
5.3 Results  
 
 
5.3.1 Baseline muscle and serum measurements in placebo and treatment groups 
 
 
There were no significant baseline differences in vastus lateralis expression of the genes 
analysed or serum measurements between the groups (table 5.2). 
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Table 5.2: Baseline muscle biopsy and serum measurements 
 
 
 Placebo group 
mean (SD) 
Treatment group 
mean (SD) 
p 
value 
Vastus lateralis    
Atrogin-1 mRNA (AU) 2.6 (0.5) 2.4 (0.5) 0.16 
MuRF-1 mRNA (AU) 2.2 (0.7) 2.0 (0.8) 0.30 
IGF-1 mRNA (AU) 0.9 (0.5) 1.0 (0.3) 0.56 
MyoD mRNA (AU)  2.6 (0.6) 2.4 (0.7) 0.43 
TGF-β mRNA (AU) 1.3 (0.7) 1.4 (0.6) 0.74 
MHC I mRNA (AU) 3.9 (0.7) 4.2 (0.5) 0.11 
MHC IIA mRNA (AU) 4.6 (0.5) 4.7 (0.6) 0.88 
MHC IIX mRNA (AU) 4.0 (0.7) 4.1 (0.6) 0.78 
Phosphorylated 4EBP-1 protein (AU) 2.2 (0.5) 2.0 (0.6) 0.56 
Serum  
 
 
 
ACE activity (IU/L) 48.0 (28.0) 43.5 (15.3) 0.43 
HS-CRP (mg/L) 9.8 (21.0) 4.6 (4.6) 0.18 
Fibrinogen (g/L) 2.6 (0.69) 2.8 (0.67) 0.20 
IGF-1 (ug/L) 124.6 (61.5) 145.0 (103.8) 0.32 
IL-6 (ng/L) 4.6 (15.2) 1.9 (2.5) 0.34 
IL-8 (ng/L) 3.7 (3.5) 4.0 (2.8) 0.69 
IL-18 (ng/L) 494.9 (332.7) 421.0 (174.7) 0.27 
MCP-1 (ng/L) 66.2 (43.3) 77.7 (37.0) 0.26 
 
Abbreviations: MuRF-1 – muscle RING finger protein-1; IGF-1 – insulin-like growth factor-1; 
ACE – angiotensin-converting enzyme; HS-CRP – high-sensitivity C-reactive protein; IL – 
interleukin; MCP-1 – monocyte chemotactic protein-1.  
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5.3.2 Effect of ACE-inhibition on vastus lateralis atrophy/hypertrophy signalling 
 
 
At 3 months, no significant differences were observed in vastus lateralis atrogin-1 mRNA 
expression (fosinopril ∆-0.18AU, 95%CI -0.41 to 0.04, p=0.11 vs. placebo ∆-0.15AU, 95%CI -
0.35 to 0.04, p=0.12; between group difference, -0.03AU, 95%CI -0.32 to 0.26, p=0.84) 
(figure 5.1) or MuRF-1 mRNA expression (fosinopril ∆0.09AU, 95%CI -0.21 to 0.39, p=0.55 
vs. placebo ∆-0.13AU, 95%CI -0.32 to 0.05, p=0.14; between group  difference, 0.22AU, 
95%CI -0.11 to 0.55, p=0.18) (figure 5.2). Vastus lateralis IGF-1 mRNA expression also 
showed no significant difference between groups (0.04AU, 95%CI -0.38 to 0.46, p=0.84) at 
3 months. In addition, no significant differences were found in MyoD, TGF-β and MHC 
isoform mRNA expression between the groups at 3 months (see table 5.3), although MHC 
type I mRNA did show a trend towards a reduction in the treatment group (p=0.06) (figure 
5.3). 
 
 
5.3.3 Effect of ACE-inhibition on serum ACE activity, IGF-1 and inflammatory markers 
 
 
The treatment group demonstrated a significant reduction in serum ACE activity compared 
to placebo (fosinopril ∆-17.4IU/L, 95%CI -28.1 to -6.8, p=0.002 vs. placebo ∆3.0IU/L, 95%CI 
-1.2 to 7.1, p=0.15; between group difference, -20.4IU/L, 95%CI -31.0 to -9.8, p=0.0003) 
(figure 5.4). No significant differences were found in serum IGF-1, HS-CRP, NT-pro BNP, 
fibrinogen or serum inflammatory cytokines between the groups at 3 months (see table 
5.3).  
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Table 5.3: Change in muscle biopsy and serum measurements after 3 months of ACE-
inhibition 
 
 
 
 
Placebo group 
mean (SD) 
Treatment group 
mean (SD) 
p 
value 
Vastus lateralis    
Atrogin-1 mRNA (AU) -0.16 (0.5) -0.19 (0.5) 0.84 
MuRF-1 mRNA (AU) -0.13 (0.5) 0.09 (0.7) 0.18 
IGF-1 mRNA (AU) 0.34 (0.5) 0.43 (0.9) 0.65 
MyoD mRNA (AU) -0.08 (0.5) -0.4 (1.2) 0.23 
TGF-β mRNA (AU) 0.21 (0.9) 0.12 (1.1) 0.77 
MHC I mRNA (AU) -0.13 (0.6) -0.59 (1.0) 0.06 
MHC IIA mRNA (AU) -0.16 (0.6) -0.39 (1.2) 0.36 
MHC IIX mRNA (AU) 0.004 (0.9) -0.13 (0.8) 0.64 
Phosphorylated 4EBP-1 protein (AU) -0.18 (0.6) 0.18 (0.6) 0.08 
Serum    
ACE activity (IU/L) 3.0 (12.0) -17.4 (28.5) 0.0003 
HS-CRP (mg/L) -0.52 (31.2) 4.1 (13.0) 0.45 
NT-proBNP (ng/L) -3.7 (55.6) -9.1 (42.0) 0.66 
Fibrinogen (g/L) 0.17 (0.9) 0.03 (0.6) 0.49 
IGF-1 (ug/L) 8.9 (34.8) -9.5 (64.3) 0.14 
IL-6 (ng/L) 1.7 (9.8) 1.3 (6.1) 0.84 
IL-8 (ng/L) 0.65 (3.0) 0.65 (1.8) 0.99 
Il-18 (ng/L) 46.4 (134.4) 62.2 (164.9) 0.67 
MCP-1 (ng/L) -2.5 (30.0) -5.9 (26.4) 0.63 
 
Abbreviations: MuRF-1 – muscle RING finger protein-1; IGF-1 – insulin-like growth factor-1; ACE – 
angiotensin-converting enzyme; HS-CRP – high-sensitivity C-reactive protein; NT-proBNP – N-terminal 
pro-B-type natriuretic peptide; IL – interleukin; MCP-1 – monocyte chemotactic protein-1. 
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Figure 5.1: Atrogin-1 vastus lateralis mRNA expression following 3 months ACE-inhibition 
(Data shown as mean with cross bars representing SEM; not significant - NS). 
 
 
Figure 5.2: MuRF-1 vastus lateralis mRNA expression following 3 months ACE-inhibition  
(Data shown as mean with cross bars representing SEM; not significant - NS). 
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Figure 5.3: MHC I vastus lateralis mRNA expression following 3 months ACE-inhibition 
(Data shown as mean with cross bars representing SEM; not significant - NS). 
 
 
Figure 5.4: Serum ACE activity following 3 months ACE-inhibition  
(Data shown as mean with cross bars representing SEM; not significant - NS).  
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5.3.4 Influence of ACE/bradykinin polymorphisms  
 
 
The response to ACE-inhibition vs. placebo was also assessed by ACE and bradykinin 
receptor genotype as shown in table 5.4. When divided by ACE genotype, no significant 
differences were seen in vastus lateralis mRNA expression for the genes analysed. Patients 
homozygous for the insertion allele (II) showed a significant reduction in serum MCP-1 
following treatment (fosinopril ∆-45.1ng/L vs. placebo ∆+3.3ng/L) when compared to 
other genotypes; DD genotype (fosinopril ∆+1.3ng/L vs. placebo ∆+2.9ng/L), ID genotype 
(fosinopril ∆-0.7ng/L vs. placebo ∆-11.2ng/L) (ANOVA p=0.01). In a separate analysis for 
treatment response by presence of an I allele (ID and II vs DD), no significant difference 
was found for serum MCP-1 (p=0.91). 
 
When analysing bradykinin receptor genotypes, only serum IGF-1 showed a difference in 
treatment response (-9/-9 genotype; fosinopril ∆+23.7ug/L vs. placebo ∆-13.8ug/L) vs (+9/-
9 genotype; fosinopril ∆-2.8ug/L vs. placebo ∆+18.2ug/L) vs. (+9/+9 genotype; fosinopril ∆-
46.6ug/L vs. placebo ∆+12.0ug/L) (ANOVA p=0.02). In a separate analysis for treatment 
response by presence vs. absence of the -9 allele, (-9/-9 and +9/-9 vs. +9/+9) a significant 
difference in serum IGF-1 was also found (-9/-9 and +9/-9 genotype; fosinopril ∆+6.0ug/L 
vs. placebo ∆+7.0ug/L) vs. (+9/+9 genotype; fosinopril ∆-46.6ug/L vs. placebo ∆+12.0ug/L) 
(p=0.03). 
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Table 5.4: Change in mRNA expression and serum measurements following 3 months ACE-
inhibition when stratified by ACE genotype. 
 
 
 
Change in treatment vs. 
placebo 
stratified by ACE genotype  
(DD vs. ID vs. II) 
p value (ANOVA) 
Change in treatment vs. placebo 
 stratified by bradykinin 
polymorphism 
(+9/+9, -9/+9, -9/-9) 
p value (ANOVA) 
Vastus Lateralis   
Atrogin-1 mRNA 0.37 0.63 
MuRF-1 mRNA 0.95 0.99 
IGF-1 mRNA 0.99 0.28 
MyoD mRNA (AU) 0.49 0.97 
TGF-β mRNA (AU) 0.93 0.38 
MHC I mRNA (AU) 0.38 0.70 
MHC IIA mRNA (AU) 0.18 0.98 
MHC IIX mRNA (AU) 0.24 0.84 
Phosphorylated 4EBP-1 (AU) 0.57 0.34 
Serum   
ACE activity (IU/L) 0.78 0.81 
HS-CRP (mg/L) 0.78 0.93 
NT-proBNP (ng/L) 0.99 0.93 
Fibrinogen (g/L) 0.29 0.12 
IGF-1 (ug/L) 0.98 0.02 
IL-6 (ng/L) 0.22 0.27 
IL-8 (ng/L) 0.30 0.36 
Il-18 (ng/L) 0.80 0.52 
MCP-1 (ng/L) 0.01 0.07 
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5.3.5 Vastus lateralis atrophy/hypertrophy signalling in COPD vs. healthy subjects 
 
 
A sub-study was conducted to investigate baseline atrophy/hypertrophy signalling in the 
COPD patients participating in the trial when compared to healthy subjects. Demographics 
are shown in table 5.5; the two groups were well-matched for age, gender, BMI and FFMI. 
Quadriceps strength (QMVC) and ultrasound measurement of rectus femoris cross-
sectional area (USRFCSA) were significantly lower in COPD patients compared to the healthy 
controls.  
 
Table 5.5: Baseline demographics COPD vs. healthy controls sub-study 
 
 
COPD (n=50) 
mean (SD) 
Controls (n=11) 
mean (SD) 
p 
value 
Age 65.9 (7.2) 64.5 (6.3) 0.54 
Gender (M/F) 33/17 7/4 0.88 
BMI (kg/m2) 25.3 (4.9) 26.6 (3.2) 0.42 
FFMI (kg/m2) 17.7 (2.3) 18.4 (2.1) 0.37 
FEV1% predicted 43.1 (21.1) 96.3 (9.8) <0.0001 
QMVC (kg) 26.9 (6.1) 38.1 (11.2) <0.0001 
USRFCSA (mm
2) 537 (121) 704 (107) 0.0006 
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Following vastus lateralis muscle biopsy analysis using RT-qPCR, IGF-1 mRNA expression 
was significantly reduced in the COPD subjects compared to healthy age matched controls 
(p=0.03) (figure 5.5). No significant differences were found between COPD subjects and 
healthy controls for Atrogin-1 (p=0.44) and MuRF-1 (p=0.92) mRNA expression (figures 5.6 
and 5.7). MyoD mRNA expression was reduced in COPD patients compared to healthy 
controls (p=0.006) (figure 5.8).  
 
Analysis of MHC isoforms showed MHC type I mRNA expression was reduced in COPD 
patients compared to healthy controls (p=0.01) (figure 5.9). No significant differences were 
found in MHC type IIA (p=0.54) and IIX (p=0.45) expression (figures 5.10 and 5.11). 
Phosphorylated 4EBP-1, measured by ELISA, was increased in COPD patients compared to 
healthy subjects (p=0.04) (figure 5.12). 
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Figure 5.5: IGF-1 vastus lateralis mRNA expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
 
 
Figure 5.6: Atrogin-1 vastus lateralis mRNA expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
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Figure 5.7: MuRF-1 vastus lateralis mRNA expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
 
Figure 5.8: MyoD vastus lateralis mRNA expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
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Figure 5.9: MHC I vastus lateralis mRNA expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
 
 
Figure 5.10: MHC IIA vastus lateralis mRNA expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
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Figure 5.11: MHC IIX vastus lateralis mRNA expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
 
Figure 5.12: 4EBP-1 vastus lateralis protein expression in COPD subjects vs. controls  
(Cross bars represent standard error of the mean - SEM).  
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5.4 Discussion  
 
 
5.4.1 Summary of results 
 
 
Fosinopril did not have an effect on vastus lateralis atrophy/hypertrophy signalling or 
serum inflammatory markers in COPD patients selected for quadriceps weakness, although 
measurement of serum ACE activity confirmed both adherence and biological activity of 
the drug. This data does not support the use of ACE inhibitors as a therapy for muscle 
wasting in patients with COPD.    
 
 
5.4.2 Significance of the findings 
 
 
Despite evidence from animal models of the ability to prevent angiotensin II induced 
cachexia via IGF-1 overexpression and atrogene downregulation (Yoshida 2010), ACE-
inhibition was not shown to have any translational effect on the quadriceps in COPD 
patients.  In particular, the molecular data from the trial demonstrates that, at least over a 
3 month period, fosinopril did not alter atrophy signalling at a tissue level, despite a clear 
systemic effect on serum ACE activity. There is evidence to suggest this systemic effect 
would have inhibited tissue ACE (Erman 1991), however it is important to note that local 
tissue renin-angiotensin systems can generate angiotensin II, independent of ACE activity, 
through serine proteases such as cathepsins and chymase (Lorenz 2010). In particular, 
intracellular angiotensin II generation is mediated via these enzymes with cathepsin D 
utilised in place of renin for tissue conversion of angiotensinogen, and chymase rather 
than ACE catalysing the subsequent production of angiotensin II (Kumar 2008). This may 
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explain the lack of influence of ACE-inhibition on skeletal muscle observed in this trial and 
account for the potential benefits seen with angiotensin receptor blockade in other 
studies. Recent evidence has also highlighted the complexity of molecular targets 
mediating response to RAS modulation in skeletal muscle. In particular, preventing the 
activation of TGF-β using a losartan derivative to inhibit AT1 receptor activation has been 
recently shown to restore skeletal muscle regeneration in a congenital muscular dystrophy 
mouse model (Meinen 2012). This supports previous work identifying losartan in restoring 
muscle structure and function in a dystrophin deficient mouse model again through 
inhibiting the activation of TGF-β (Cohn 2007). Therefore, although ACE-inhibition did not 
influence vastus lateralis gene expression in this trial, the evidence in relation to 
modulation of TGF-β signalling using AT1 receptor blockade highlights the potential 
importance of this pathway over the IGF-1/atrogene axis in COPD. The relative influence of 
these key signalling targets has recently been investigated in a study by Burks et al, who 
found that while losartan improved skeletal muscle repair in response to injury via a 
inhibition of TGF-β in a sarcopenic mouse model, its ability to protect against loss of 
muscle mass in a mouse disuse atrophy model was mediated via modulation of the        
IGF-1/mTOR cascade (Burks 2011). This highlights the complexity of the 
atrophy/hypertrophy signalling in skeletal muscle, particularly in response to differing 
insults. The dominant influence of physical inactivity on the IGF-1 axis in the trial patients 
may well have confounded any effect from RAS blockade. 
 
In addition, recent work using RAS inhibition in an emphysema mouse model and in lung 
biopsies from COPD patients (Podowski 2012) has found that cigarette smoking induced 
alveolar emphysematous injury and airway epithelial hyperplasia were associated with 
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enhanced signalling of TGF-β. Losartan normalised oxidative stress markers, 
metalloprotease activation and elastin remodelling through TGF-β inhibition. These data 
support work by Raupach et al who found benefits in histological emphysema severity, 
lung compliance and exercise capacity following treatment with irbesartan in an 
emphysema mouse model (Raupach 2011). The use of ACE-inhibition rather than AT1 
receptor blockade may account for the absence of an effect on serum inflammatory 
markers as well as lung function parameters in the COPD patients in this trial.  
 
Skeletal muscle impairment in COPD involves both fibre atrophy and fibre shift away from 
an oxidative, fatigue resistant phenotype (Gosker 2007). When assessing MHC isoform 
expression in the vastus lateralis, a trend towards a reduction in MHC type I expression 
was observed in patients in the treatment arm. This supports the possibility of an effect of 
ACE-inhibition on the intramuscular environment with a potentially reduced skeletal 
muscle blood flow influencing muscle phenotype. However it is important to note that the 
observed trend may also represent a regression to the mean given the trend towards 
higher MHC type I mRNA expression in the treatment group at baseline. In addition, this 
trend goes against a previous small study of 16 patients with congestive cardiac failure 
which assessed the effects of 6 months treatment with enalapril (n=8) or losartan (n=8) on 
maximal cardiopulmonary exercise capacity and myosin heavy chain composition of the 
gastrocnemius (Vescovo 1998). They found an improvement in exercise capacity in both 
groups and a significant shift from MHC type IIa to MHC type I composition following 
treatment. In particular in this small sample size, the magnitude of MHC type I change 
correlated significantly with net peak V(O2) gain.   
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Interestingly, the D allele of the ACE (I/D) polymorphism which is associated with higher 
ACE activity, has been previously associated with greater quadriceps strength in COPD 
patients (Hopkinson 2004b). In this trial stratification by genotype did not reveal any 
differences in vastus lateralis gene expression; however patients homozygous for the 
insertion allele (II) did have a significant reduction in serum MCP-1 with treatment 
compared to placebo. As the trial was not prospectively designed to stratify patients by 
genotype, the numbers of homozygous (II) patients was small and this finding was not 
maintained when analysing patients by presence of a single I allele. Further work is 
therefore needed to establish if any true variation in response exists with genotype. In 
addition when stratifying by bradykinin receptor genotype, serum IGF-1 was significantly 
reduced following treatment in patients who did not exhibit the -9 allele. The absence of 
this allele is associated with lower BK(2)R receptor expression, and in patients with COPD 
has been associated with a reduced fat free mass and reduced quadriceps strength 
(Hopkinson 2006). It may be the case that these patients respond differently to ACE-
inhibition and further interventional studies prospectively designed to stratify by genotype 
are needed to investigate this.  
 
 
Vastus lateralis signalling in COPD patients vs. controls 
 
 
When considering the recent evidence comparing quadriceps atrophy/hypertrophy 
signalling in COPD subjects with healthy controls there is a suggestion of an equivocal role 
for IGF-1 dysregulation in the pathogenesis of skeletal muscle atrophy in COPD. Our sub-
study finding of a reduction in IGF-1 expression in COPD patients with quadriceps 
weakness compared to healthy subjects, is supported by data in patients hospitalised with 
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an acute exacerbation of COPD (n=14) vs. controls (Crul 2007). However, an elevation in 
IGF-1 expression has been observed in other COPD cohorts (Debigare 2008; Lewis 2012) 
suggesting that IGF-1 signalling may be highly dependent on patient phenotype and the 
context of sampling. A polypeptide repressor downstream of IGF-1/mTOR signalling, 
known as eukaryotic translation initiation factor 4E binding protein (4EBP-1) (see figure 
1.2), was also investigated in the sub-study. 4EBP-1 is inhibited by mTOR through 
phosphorylation so as to promote protein synthesis (Fingar 2002). We found that 
phosphorylated 4EBP-1 was significantly greater in COPD patients with quadriceps 
weakness compared to healthy controls, consistent with previous evidence (Doucet 2007). 
When considered in the context of reduced IGF-1 expression, this highlights the possibility 
of IGF-1 independent mechanisms acting to signal an increase in protein synthesis and also 
indicates an element of synthetic resistance in the quadriceps in COPD.  
 
Our finding of no difference in MuRF-1 and atrogin-1 expression in COPD patients with 
quadriceps weakness versus healthy controls also suggests that the role for these ubiquitin 
ligases in mediating skeletal muscle dysfunction in COPD may in fact be less pivotal than 
was previously thought. It has been shown that MuRF-1 and atrogin-1 signalling in 
response to rehabilitation can vary depending on COPD patient body composition with a 
reduced expression observed following rehabilitation in non-cachectic patients compared 
to an elevated expression in a cachectic group (Vogiatzis 2010). As our COPD population 
was already weak it may be the case that elevation of the atrogenes at this late stage of 
muscle atrophy was no longer necessary explaining the similarity in expression to controls. 
Interestingly, MyoD expression was found to be reduced in COPD patients with quadriceps 
weakness compared to controls highlighting that there may be an ongoing attenuated 
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response from myogenic satellite cells to muscle injury in these patients (i.e. a reduced 
ability for regeneration). In support of this, resistance training in COPD patients 
hospitalised for an acute exacerbation has been shown to be associated with increased 
MyoD expression and improved quadriceps force compared to usual care (Troosters 
2010b). MyoD may therefore represent an important future target for novel therapies 
including AT1 receptor blockade in COPD. 
 
 
5.4.3 Critique of the method 
 
 
A strength of this study was the inclusion of molecular outcomes derived from the vastus 
lateralis muscle biopsies and serum samples, in addition to the physiological outcomes 
discussed in the previous chapter. The number of patients studied was limited however 
due to some declining the muscle biopsy and others where the sample obtained was 
insufficient for q-PCR analysis. Despite this, an adequate number of paired samples were 
obtained for statistical power in the study findings.  
 
It is important to note that the mechanisms of intracellular angiotensin II generation, 
detailed above, would suggest that therapy using an AT1 receptor blocker may have 
enabled better testing of the effect of RAS modulation on skeletal muscle. In addition the 
molecular targets for this trial were based on the role of MuRF-1 and atrogin-1 atrophy 
signalling in the skeletal muscle dysfunction observed in COPD and the dysregulation of 
IGF-1/mTOR signalling in these patients. However it is increasingly clear from the literature 
that skeletal muscle impairment in COPD involves a number of signalling cascades which 
have an influence on the balance of protein synthesis and breakdown. Identifying the 
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targets likely to have a central role in muscle dysfunction and which can be effectively 
modulated remains a focus for future studies. Importantly, key factors including physical 
inactivity, nutritional status, underlying COPD phenotype, and the patients stage in the 
muscle wasting process (i.e. cachectic – end-stage vs. early wasting) may all have a more 
profound effect on the expression of these signalling targets than any one pharmacological 
intervention alone. The participants from this trial were weak and well advanced in the 
wasting process, thereby potentially limiting the response to a single intervention.  
 
 
5.4.4 Conclusion 
 
 
In summary, this double-blinded randomised controlled trial found that ACE-inhibition, in 
the form of fosinopril, did not reduce atrogene expression in a COPD population with 
quadriceps weakness. This study does not support a beneficial role for ACE-inhibitors in 
skeletal muscle atrophy/hypertrophy signalling in patients with COPD.  
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Chapter 6: General Discussion and 
Future Work 
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6.1 Quadriceps wasting and physical inactivity in mild COPD  
 
 
6.1.1 Implications and future work 
 
 
Previous studies investigating quadriceps mass and strength in COPD have reported 
skeletal muscle dysfunction as a feature of patients with end-stage disease, judged by their 
degree of airflow obstruction (Bernard 1998). However, the findings from this thesis that 
quadriceps wasting exists in COPD patients with mild, as well as more advanced, disease 
support recent retrospective data where quadriceps weakness was identified in 
approximately one third of COPD outpatients ranging across all stages of disease severity 
(Seymour 2010b). In addition, quadriceps endurance has been shown to be impaired in 
mild to moderate COPD patients compared to healthy subjects (Coronell 2004) and very 
recently a loss of vastus lateralis oxidative phenotype has been identified in the early 
stages of the disease (van den Borst 2012).  
 
The onset and progression of skeletal muscle loss in COPD patients requires further 
research in the form of large longitudinal studies and it is likely that the natural history of 
muscle dysfunction in these patients will be linked to the underlying aetiology, as well as 
COPD phenotype. A number of potential factors are thought to contribute to muscle 
dysfunction in these patients including genetic predisposition, malnutrition, systemic 
inflammation and in particular, physical inactivity. The findings in this thesis of a reduction 
in physical activity in COPD patients with mild disease compared to healthy age-matched 
controls and its association with a reduced quadriceps rectus femoris cross-sectional area 
and quadriceps strength highlight the potential influence of this factor early in the disease 
process.  The cause or effect aspect of this relationship remains to be determined however 
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the evidence suggests a disease spiral incorporating breathlessness, inactivity and muscle 
dysfunction (Figure 6.1) (Polkey 2011). Importantly, the association between reduced 
health status and muscle dysfunction shown in this thesis highlights the likely influence of 
this disease spiral on quality of life for these patients.   
 
 
 
Figure 6.1: The disease spiral in COPD  
adapted from (Polkey 2011) 
 
It may be the case that loss of muscle mass and reduced physical activity represent an 
accelerated ageing process in the muscle of COPD patients, as has been postulated in the 
lung through cigarette smoking and inflammation (Ito 2009). Many of the mechanisms 
related to sarcopenia including disuse atrophy, oxidative stress and modulation of the IGF-
1-PI3K/AKT pathway (Giovannini 2008), are thought to influence the muscle dysfunction 
observed in COPD patients. In addition to an underlying accelerated aging process in the 
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muscle, specific insults relating to COPD phenotype can further compromise muscle 
function in these patients over time. Patients with an exacerbator phenotype may have 
recurrent episodes of hypoxia, inflammation and immobilisation as part of an acute 
exacerbation of their COPD, which can lead to progressive stepwise deteriorations in 
muscle function. In this context, recent evidence has shown that early exercise 
intervention both as an outpatient after an acute exacerbation (Seymour 2010a) or whilst 
an inpatient (Troosters 2010b), results in improvements in quadriceps strength in this 
patient group. Another important phenotype are COPD patients who, during the course of 
their disease, develop a severe systemic inflammatory response leading to a cachexia 
syndrome with rapid loss of function (Steiner 2012). These patients often have a poor 
prognosis and, due to the severity of their condition, interventions such as exercise 
programs are often not possible.  
 
Therefore, the identification of patients with quadriceps wasting particularly in the early 
stages of COPD is paramount to enable early interventions to alter this disease spiral. In 
particular, this thesis has identified ultrasound of the rectus femoris as a potential non-
invasive, radiation-free tool to assess quadriceps size in COPD patients. Interestingly, a 
current randomised controlled trial of early rehabilitation in critical care is utilising 
ultrasound of the rectus femoris to detect response to functional electrical stimulation 
(Parry 2012). Further trials are needed in large COPD populations to establish the ability of 
ultrasound to detect peripheral muscle response to interventions. 
 
This thesis has also highlighted a potential use for multiple frequency bio-electrical 
impedance analysis as another non-invasive technique that could be used to identify GOLD 
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stage I and II patients with quadriceps weakness in the community. This measurement 
provides an impedance ratio (Z200/Z5), as a marker of extracellular to total body water and 
cell membrane integrity, and this ratio is associated with reduced quadriceps strength and 
size in COPD patients. Interestingly, as neurohormonal activation and actions of the renin-
angiotensin system (RAS) lead to sodium and water retention, there is likely to be an 
influence on body water distribution in COPD. This, in combination with the effect of RAS 
on body composition through muscle atrophy, may explain the relationship between the 
impedance ratio and quadriceps strength.  In subjects with heart failure, who have 
reduced muscle mass and a reduced level of physical activity similar to COPD, the 
impedance ratio has been shown to be associated with handgrip strength and New York 
Heart Association (NYHA) functional class severity (Castillo Martinez 2007). The impedance 
ratio may provide a valuable marker in the clinical setting to stratify weakness in COPD 
patients. Further work however is needed with regards to analysing its use in a 
longitudinal setting and in response to interventions such as pulmonary rehabilitation. 
 
The role of pulmonary rehabilitation as an evidence-based treatment for improving 
exercise tolerance in COPD patients is well-documented (Lacasse 2006; Troosters 2010c) 
however the relationship between daily physical activity and exercise capacity has been 
shown to be moderate to weak in COPD patients (Zwerink 2013). This is in keeping with 
baseline cross-sectional data from this thesis showing a similar degree of association 
between incremental shuttle walk distance and daily step count in COPD patients (r2=0.25, 
p<0.0001). Importantly, recent evidence assessing the short and long term effects of a 7-
week pulmonary rehabilitation program has found that increases in exercise capacity do 
not translate to increases in daily physical activity (Egan 2012). These findings highlight 
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that effecting behavioural change with regards to physical activity remains a key challenge 
(Probst 2011) and this has particular relevance in early disease as moderate to high levels 
of physical activity have been associated with reduced lung function decline and risk of 
developing COPD in smokers (Garcia-Aymerich 2007). An increased focus on interventions 
that combine the targeting of physical inactivity with muscle dysfunction in mild disease 
remains a central aim for future studies in this research field.   
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6.2  Renin-angiotensin system blockade and muscle dysfunction in COPD 
 
 
6.2.1 Implications and future work 
 
 
Although pulmonary rehabilitation remains the mainstay of therapy for muscle 
dysfunction in COPD, inherent difficulties with accessibility and availability of these 
exercise programs limit their uptake and adherence for many patients. Therefore there 
may be a role for an ‘exercise pill’ through the development of novel pharmacological 
therapies targeting the skeletal muscles in COPD (Goodyear 2008). In particular, work by 
Narkar et al has identified that the use of a PPAR beta/delta agonist with exercise 
synergistically increased oxidative myofibres and running endurance in adult mice (Narkar 
2008). In addition, the authors investigated the energy sensor AMP-activated protein 
kinase (AMPK) known to be activated during training and found that 4 weeks treatment 
with the AMPK agonist - AICAR, improved running endurance by 44% in sedentary mice. 
Importantly, elevated phosphorylated AMPK levels have recently been associated with an 
increase in non-volitional quadriceps endurance in COPD patients (Natanek 2012) and 
therefore the AICAR data highlights the potential role of pharmacotherapy both in the 
augmentation of rehabilitation programs or in some cases as an alternative treatment.  
 
When assessing ACE-inhibition as one such therapy, this thesis did not find fosinopril to 
improve skeletal muscle dysfunction in COPD patients with quadriceps weakness. As 
previously discussed, a number of factors may have influenced the outcome of the trial 
and future studies should include a wider cohort of COPD patients with muscle 
dysfunction, test other therapies for RAS blockade and prospectively stratify patients by 
ACE genotype. In particular, there is also evidence to suggest that RAS blockade may have 
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benefit during exercise therapy in augmenting the effects on exercise capacity. Bradykinin 
is synthesised in skeletal muscle during exercise (Langberg 2002) and therefore may exert 
an enhanced effect during training. The potential adjunctive effect of ACE-inhibition with 
exercise was highlighted in a recent study in which old female rats were treated with 
exercise training, perindopril or both interventions together over a 6 month period. The 
study found that the combination treatment increased type I fibre percentage in the 
gastrocnemius muscle when compared with exercise training alone (Guo 2010).  An 
increase in capillary density in the soleus and gastrocnemius muscles was also shown with 
the addition of ACE-inhibition to exercise training, suggesting that perindopril may help 
promote the adaptive changes in response to exercise. Furthermore, a recent study has 
shown that angiotensin II induced oxidative stress can inhibit mitochondrial respiration in 
skeletal muscle and limit exercise capacity suggesting a potential mechanism for the 
effects of ACE-inhibition with exercise (Inoue 2012). To further explore this hypothesis at a 
translational level, an MRC funded trial is currently underway in COPD patients 
investigating the effect of enalapril in improving exercise capacity during a pulmonary 
rehabilitation program, using peak workload from cycle ergometry as the primary outcome 
measure.  
 
Recent work has also postulated RAS blockade as a potential strategy to slow the ageing 
process, via its protective effects on mitochondria (de Cavanagh 2011). Mitochondria are a 
key cellular source of ROS as well as being a target for ROS-dependent injury. Angiotensin 
II can depress mitochondrial energy metabolism through the stimulation of free radicals 
and can downregulate PPAR’s which have been identified in models of calorific restriction 
to have a role in delaying the ageing process, through regulation of mitochondria. The 
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actions of RAS blockade in preventing oxidative stress and activating PPAR’s may therefore 
play a role in promoting anti-ageing effects in skeletal muscle mitochondria. Of note, 
telmisartan enhances skeletal muscle endurance through activation of the PPAR delta 
pathway (Feng 2011) and has recently been proposed as a metabolic modulator in the 
context of performance enhancing drugs in sport (Sanchis-Gomar 2012).  
 
Another potentially important target for future investigation is the interaction of sirtuins 
with the renin-angiotensin system. Sirtuins are protein deacetylases implicated in the 
regulation of metabolism, stress responses and aging. Evidence for this link comes from 
the observed prolongation of lifespan in mice following targeted disruption of the 
angiotensin II type 1 receptor gene (Benigni 2009). This was found to be associated with an 
upregulation of renal sirtuin 3 and reduction in oxidative injury when compared to wild-
type mice. Furthermore the investigators found that in cultured tubular epithelial cells, 
angiotensin II downregulated sirtuin 3 mRNA, with AT1 antagonists shown to inhibit this 
effect. Resevatrol, a polyphenol found in red wine, has been shown to downregulate AT1 
receptor expression in vascular smooth muscle cells through activation of sirtuin 1 
(Miyazaki 2008) highlighting a potential longevity effect mediated thorough RAS blockade. 
Furthermore angiotensin II has also been shown to induce muscle protein degradation via 
NF-κB (Russell 2006). Increased NF-κB signalling is thought to contribute to accelerated 
ageing and importantly, sirtuin 6 has been shown to inhibit this effect through histone (H3 
lysine 9) deacetylation (Kawahara 2009; Natoli 2009). The role of sirtuin and RAS 
interaction in skeletal muscle dysfunction in COPD therefore holds potential as a key area 
of research interest in the context of accelerated aging in this patient group. 
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One other potential area of future research relates to the emergence of non-coding RNA 
molecules – microRNAs.  The modulation of TGF-β  by RAS blockade highlights this 
potential link given the recently identified interaction between TGF-β signalling and 
microRNAs in the lung tissue of patients with COPD (Ezzie 2012). These microRNAs reduce 
mRNA half-life and translation and may therefore influence both pulmonary and 
extrapulmonary manifestations of COPD. Recent evidence has  identified microRNA-1 
expression to be associated with smoking history, FEV1, fat-free mass index and 6-minute 
walk distance in COPD patients (Lewis 2012). Further research is required to understand 
the role of these microRNA’s and their possible interaction with RAS in the pathogenesis of 
the disease. 
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6.3  RAS blockade and cardiovascular comorbidity in COPD 
 
 
6.3.1 Future directions  
 
 
RAS blockade may have a role in other aspects of the treatment of COPD. In particular, 
cardiovascular disease is now recognised as a key co-morbidity in these patients with a 
significant impact on mortality (Sin 2006). Epidemiological evidence suggests that more 
than 40% of COPD patients have concomitant cardiac disease - chronic heart failure being 
the most common (Chatila 2008). The increased risk of ischaemic heart disease (Soriano 
2005), subclinical left ventricular dysfunction (Flu 2010), and elevated right ventricular 
pressures (Sabit 2010) in COPD have led to the suggestion that a more aggressive 
approach to the cardiovascular assessment and treatment of these patients may be 
justified (Fabbri 2011; Nussbaumer-Ochsner 2011; Rabe 2011). The importance of cardiac 
involvement has recently been highlighted by the identification of troponin T (Hoiseth 
2011) and N-terminal pro-B-type natriuretic peptide (NT-BNP) (Chang 2011) as biomarkers 
in predicting risk of death for patients hospitalised with an exacerbation of COPD. In 
addition, low grade systemic inflammation in the form of elevated CRP has been 
associated with an increased risk of cardiac ischaemia based on electrocardiogram (ECG) 
scoring in moderate-severe COPD (Sin 2003). In this context, the potential mortality 
benefit of ACE-inhibition has been assessed in a large retrospective study in elderly 
patients hospitalised for a COPD exacerbation (Mortensen 2009). The study identified that 
ACE-inhibitor or ATII receptor blocker use, when controlling for demographics, co-
morbidities and other medications, was significantly associated with a decreased 90-day 
mortality following their COPD hospital presentation (odds ratio 0.55, 95% confidence 
interval 0.45-0.66). This data supports previous work by Mancini et al, who performed a 
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nested case-control study incorporating 946 COPD patients divided into two retrospective 
cohorts based on cardiac risk profile. They found that a combination of statin and ACE-
inhibitor or angiotensin receptor blocker was associated with a reduction in COPD 
hospitalisation and mortality in both high and low cardiovascular risk groups (Mancini 
2006). A greater understanding of the potential dual cardiopulmonary actions behind this 
effect will help to evaluate the role of these interventions in COPD disease modification.  
 
The depth of the field of ACE-inhibition and its potential benefits in the COPD population 
has also been highlighted by a recent meta-analysis published in the British Medical 
Journal on the potential protective role of ACE-inhibitors in the context of pneumonia 
(Caldeira 2012). The analysis found that treatment with ACE-inhibitors was associated with 
a one-third reduction in risk of pneumonia compared with control treatment and 
angiotensin receptor blockers. In addition, ACE-inhibitors were found to reduce the risk of 
pneumonia-related mortality although the evidence was less robust.  Nevertheless, this 
highlights the intriguing possibility of a protective effect from the enhanced cough reflex in 
patients on ACE-inhibitors. Although the populations studied were only those with high 
cardiovascular risk requiring an ACE-inhibitor, this represents an important area for future 
randomised controlled trials of ACE-inhibition in patients with COPD.  
 
Overall, further work is needed to establish the impact of RAS blockade as a novel 
treatment strategy in COPD and given the variation in phenotypes, it is likely that only 
large randomised clinical trials, similar to those seen in cardiac populations, will enable us 
to elucidate the true therapeutic and survival benefits of this intervention. 
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